RyanT2021的个人主页 - 老虎社区

RyanT2021

RyanT2021

Ryan learns investing.

IP属地：未知

296关注

4粉丝

0主题

0勋章

2021-11-09

Oh yeah AMD!

抱歉，原内容已删除

2021-07-27

Nice leh

Why These 3 Microsoft Analysts Are Bullish Ahead Of Q4 Results<blockquote>为什么这三位微软分析师在第四季度业绩公布前看好</blockquote>

2021-10-07

Uh oh

抱歉，原内容已删除

2021-07-31

Like me pls

抱歉，原内容已删除

2021-11-13

Vaccine

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>

2021-08-01

I like Tsla. Like my comment pls

抱歉，原内容已删除

2021-11-26

Hooray

Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>

2021-08-25

Lol

抱歉，原内容已删除

2021-11-08

Uh oh

Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record<blockquote>供应链问题抑制了巴菲特旗下伯克希尔哈撒韦公司的利润；现金创下纪录</blockquote>

2021-10-29

Nicely

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3584238171442752","uuid":"3584238171442752","gmtCreate":1621150723051,"gmtModify":1621159965828,"name":"RyanT2021","pinyin":"ryant2021","introduction":"","introductionEn":null,"signature":"Ryan learns investing.","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":296,"tweetSize":60,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":601946359,"gmtCreate":1638487778267,"gmtModify":1638487778377,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Grabair 😒","listText":"Grabair 😒","text":"Grabair 😒","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601946359","repostId":"1191495883","repostType":2,"isVote":1,"tweetType":1,"viewCount":2456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609411200,"gmtCreate":1638317023022,"gmtModify":1638317023084,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Bad ama","listText":"Bad ama","text":"Bad ama","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609411200","repostId":"2188956532","repostType":4,"isVote":1,"tweetType":1,"viewCount":2649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609145054,"gmtCreate":1638257987846,"gmtModify":1638257987989,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Sigh new variant","listText":"Sigh new variant","text":"Sigh new variant","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609145054","repostId":"1171526526","repostType":4,"repost":{"id":"1171526526","kind":"news","pubTimestamp":1638257648,"share":"https://www.laohu8.com/m/news/1171526526?lang=zh_CN&edition=full","pubTime":"2021-11-30 15:34","market":"us","language":"en","title":"Is Omicron The Catalyst That Ushers In The Next Bear Market?<blockquote>奥密克戎是迎来下一轮熊市的催化剂吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171526526","media":"TheStreet","summary":"Investors got rattled last Friday, but could the new COVID variant be the thing that finally topples stocks?","content":"<p>There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&amp;P 500 to its largest single day loss since February and the Russell 2000 to its largest single day loss since June of last year. The reveal of a potentially more mutated and more highly contagious version of both the original COVID strain and the delta variant brought investors back to the early days of the pandemic when businesses, schools and other groups were suddenly forced to shut down.</p><p><blockquote>本周金融市场显然只有一个话题。COVID病毒omicron变种的公布让投资者陷入恐慌，并导致标普500创下自2月以来的最大单日跌幅，Russell 2000指数创下自去年6月以来的最大单日跌幅。原始新冠病毒株和德尔塔变异毒株病毒的潜在变异更多、传染性更强的版本的披露，让投资者回到了大流行初期，当时企业、学校和其他团体突然被迫关闭。</blockquote></p><p> Is it going to be as big of a deal as the markets fear it might be? It’s too early to know for sure (although the South African Medical Association seems to be&nbsp;downplaying&nbsp;the severity of it), but global governments appear to be taking no chances. Several countries have shut down their borders to people from South Africa and neighboring countries. New York has already&nbsp;declared&nbsp;a state of emergency despite no reported cases of the omicron variant. Of course, there’s still much to learn about the risk level of this COVID strain, but it’s clear that nerves are a bit frayed.</p><p><blockquote>这会像市场担心的那样重要吗？现在确定还为时过早（尽管南非医学协会似乎淡化了它的严重性），但全球政府似乎没有冒险。几个国家已经对来自南非和邻国的人关闭了边境。尽管没有奥密克戎变种病例的报告，但纽约已经宣布进入紧急状态。当然，关于这种COVID菌株的风险水平还有很多需要了解的，但很明显，神经有点紧张。</blockquote></p><p> In my opinion, Friday’s sharp equity pullback looks like a classic overreaction. Yes, there’s a distinct possibility that it may not be the bottom and equities could sell off further, but given how investors have been prolific dip buyers over the past year and expectations for the taper and future interest rate hikes turned immediately dovish, per the Fed Funds futures market, I think investors will quickly conclude that the omicron variant will likely not be as bad as anticipated and, even if it is, the Fed will quickly step in, whether it’s via a delayed taper or no rate hike until 2023, to support risk asset prices. If I’m going out on a limb, I think there’s a chance the S&amp;P 500 could recapture its all-time high (it’s currently about 2.3% below it) by the end of this week.</p><p><blockquote>在我看来，周五股市的大幅回调看起来像是典型的过度反应。是的，很有可能不是底部，股市可能会进一步抛售，但考虑到投资者在过去一年中一直是多产的逢低买家，以及对缩减购债规模和未来加息的预期立即转向鸽派，根据联邦基金期货市场，我认为投资者很快就会得出结论，奥密克戎的变体可能不会像预期的那么糟糕，即使是这样，美联储也会迅速介入，无论是通过推迟缩减购债规模还是在2023年之前不加息，以支持风险资产价格。如果我冒险的话，我认为标普500有可能在本周末重新夺回历史高点（目前比其低约2.3%）。</blockquote></p><p> Market internals had already been softening leading up to last week. Breadth within the Nasdaq 100 has been getting weaker - 30 of the 100 components have&nbsp;pulled back&nbsp;at least 20%. Small-caps have been underperforming for weeks and leadership has rotated away from cyclicals and back into tech and consumer discretionary. Treasuries are looking strong again and even gold has been seeing some action.</p><p><blockquote>直到上周，市场内部已经走软。纳斯达克100指数的广度一直在减弱——100个成分股中有30个已经回调了至少20%。小盘股几周来表现不佳，领导层已从周期性股票转向科技股和非必需消费品。美国国债看起来再次走强，甚至黄金也出现了一些走势。</blockquote></p><p> Fear is high in the markets right now and that presents opportunity. Keep a level head and watch for panic signs (e.g. the number of articles talking about how stocks could pull back 30% from here) and words from the Fed that hint at what the central bank might do. Remember, in 2020 after the initial bear market, stocks rebounded quickly as soon as the Fed and the government stepped in. If Powell pivots to a more dovish stance, U.S. equities could quickly move higher again.</p><p><blockquote>目前市场上的恐惧情绪很高，这带来了机会。保持冷静的头脑，关注恐慌迹象（例如，谈论股市如何从这里回调30%的文章数量）以及美联储暗示央行可能采取行动的言论。请记住，在最初的熊市之后的2020年，美联储和政府一介入，股市就迅速反弹。如果鲍威尔转向更加鸽派的立场，美国股市可能会迅速再次走高。</blockquote></p><p> Let’s start our weekly review by taking a look at the primary market sectors.</p><p><blockquote>让我们从一级市场板块开始我们的每周回顾。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d87d1ba9c165a777608a551646236565\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Not surprisingly, there’s little short-term strength in equities right now. Communication services remains the worst-looking of the 11 major sectors, but cyclicals are not that far behind. Energy stocks were down 4% on Friday as crude oil prices dropped more than 10%, but still managed to gain more than 1% on the week as a whole. Financials are weaker on falling interest rates, but industrials and materials are similarly well off recent highs.</p><p><blockquote>毫不奇怪，目前股市几乎没有短期走强。通信服务仍然是11个主要行业中最糟糕的，但周期性行业也不甘落后。由于原油价格下跌超过10%，能源股周五下跌4%，但全周仍上涨超过1%。由于利率下降，金融股走软，但工业和材料股同样远低于近期高点。</blockquote></p><p> As I mentioned above, tech and consumer discretionary have been the beneficiaries of rotation trades lately. Tech had become a steady outperformer before last week’s correction, while discretionary stocks have gained but remained volatile. Four of the 11 GICS sectors are now trading below their 50-day moving averages, which could be an indication that short-term momentum has run its course and it may be time for defensives to take over.</p><p><blockquote>正如我上面提到的，科技和非必需消费品最近一直是轮动交易的受益者。在上周的调整之前，科技股一直表现稳定，而非必需股有所上涨，但仍然波动。11个GICS板块中有4个目前交易价格低于50日移动均线，这可能表明短期势头已经结束，可能是时候让防御性板块接手了。</blockquote></p><p> The performance of small-caps, Treasuries and cyclicals point to more conservative positioning even before Friday. Utilities and consumer staples did relatively better as expected, but it’s been a while since either group had an extended run. This week will be telling, I think, in determining where investor risk tolerance is really at. If omicron looks like it will keep drawing out people’s fears, there might be room for defensive sectors to perform relatively well. Keep in mind that it’ll be all about business and social restrictions. If the economic impact is limited mostly to the leisure and travel sectors, the longer-term damage could be minimal.</p><p><blockquote>小盘股、国债和周期性股票的表现表明，即使在周五之前，仓位也会更加保守。公用事业和必需消费品的表现相对好于预期，但这两个行业都已经有一段时间没有长期上涨了。我认为，本周将有助于确定投资者的风险承受能力。如果奥密克戎看起来会继续引起人们的恐惧，那么防御性板块可能还有表现相对较好的空间。请记住，这将是所有关于商业和社会限制。如果经济影响主要限于休闲和旅游部门，那么长期损害可能很小。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/cbc4d98c13f73357d48d25a67a1ed80e\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p><p> Short-term strength has fallen pretty much across the board, but with a few exceptions. Semiconductor stocks had a rough week along with the rest of the tech sector, but they remain one of the best performing groups throughout 2021. Homebuilder stocks continue to build on the strength in the housing, which, despite some stops and starts in sales, demand and commodity prices, been pretty consistent.</p><p><blockquote>短期强度几乎全面下降，但也有少数例外。半导体股与其他科技股一样经历了艰难的一周，但它们仍然是2021年表现最好的股票之一。住宅建筑商股票继续在房地产市场走强的基础上上涨，尽管销售、需求和大宗商品价格出现了一些起起伏伏，但房地产市场却相当稳定。</blockquote></p><p> No surprise that the casino, leisure and recreation stocks are getting hit the hardest. These, of course, are the first to get hit in an environment like this. New travel restrictions are already being put in place and we’re very likely to see even more in the coming weeks. As we’ve seen with New York, there’s been little hesitation so far to put mitigation efforts in place. Oil prices and energy demand forecasts have taken a hit adding to the pressure.</p><p><blockquote>毫不奇怪，赌场、休闲和娱乐股受到的打击最大。当然，在这样的环境中，这些是第一批受到打击的。新的旅行限制已经实施，我们很可能在未来几周看到更多。正如我们在纽约看到的那样，到目前为止，人们毫不犹豫地采取了缓解措施。油价和能源需求预测受到打击，加剧了压力。</blockquote></p><p> No major changes in the communication services sector. We’re still seeing weakness throughout, including the social media stocks, which continue to have a hard time reversing sentiment. The traditional telecoms were virtually changed this past week and could actually become a source of support should prices continue falling here.</p><p><blockquote>通信服务板块无重大变化。我们仍然看到整体疲软，包括社交媒体股票，它们仍然很难扭转市场情绪。传统电信在过去一周几乎发生了变化，如果这里的价格继续下跌，实际上可能会成为支持的来源。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b04029e09b601d3f39d2cfc0be349d00\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Oil prices got hammered last week, which led to 5-6% losses for the explorers and servicers. The broader energy sector did comparatively better, but even clean energy posted a loss of 4% indicating little support across the board. Short-term sentiment for this sector has largely disappeared and the huge returns of earlier this year have long since been forgotten. This will be an especially omicron-dependent sector this week, so expect some above average volatility. Flow numbers show that investors are abandoning ship.</p><p><blockquote>上周油价遭受重创，导致勘探商和服务商损失5-6%。更广泛的能源板块表现相对较好，但即使是清洁能源也下跌了4%，表明几乎没有全面支持。该行业的短期情绪已基本消失，今年早些时候的巨额回报早已被遗忘。本周这将是一个特别依赖奥密克戎的行业，因此预计波动性会高于平均水平。流量数据显示投资者正在弃船。</blockquote></p><p> Just like the leisure sector, the airlines are especially weak here, but there’s really no group within the cyclicals that’s doing OK. The gold &amp; silver miners had a moment in the sun, but with gold prices appearing to have lost their momentum again, they’ve been back on the downswing. Infrastructure stock returns have largely been a function of the passage of the infrastructure bill, but that momentum it also likely to begin fading.</p><p><blockquote>就像休闲行业一样，航空公司在这里尤其疲软，但周期性行业中确实没有一个集团表现良好。黄金和白银矿商度过了一段美好的时光，但随着金价似乎再次失去动力，他们又回到了下跌趋势。基础设施股票的回报在很大程度上取决于基础设施法案的通过，但这种势头也可能开始消退。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4d74ecebe8c9240855b76ea5a23034f4\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Healthcare is starting to look a little, well, healthier again. Most of it looks like it’s due to its defensive sector peers starting to draw a little interest again, but any kind of health-related headlines, such as a new COVID variant, tend to produce at least a modest short-term bounce. Both Moderna and BioNTech, the makers of different COVID vaccines, were both up more than 20% last week alone and that’s making the biotech sector look a little stronger than it is. The&nbsp;<b>SPDR S&amp;P Biotech ETF (XBI)</b>, which equal weights the sector and gives much less weight to those names, was down 4% last week. There is some money moving back into this space, but I don’t think it’s a compelling move just yet.</p><p><blockquote>医疗保健又开始看起来有点，嗯，更健康了。这在很大程度上看起来是由于其防御性行业同行开始再次引起一些兴趣，但任何与健康相关的头条新闻，例如新的新冠病毒变种，往往至少会产生适度的短期反弹。不同新冠疫苗的制造商Moderna和BioNTech仅上周就上涨了20%以上，这使得生物技术行业看起来比实际情况要强一些。The<b>SPDR S&amp;P生物技术ETF(XBI)</b>该指数对该行业的权重相等，但对这些股票的权重要小得多，上周下跌了4%。有一些资金回流到这个领域，但我认为这还不是一个令人信服的举动。</blockquote></p><p> Not much doing on the commodities side. Crude and gasoline prices have plummeted, but natural gas prices have held their ground. I suspect that there’s some mean reversion in energy prices following Friday’s overreaction. The dollar remains very strong against the basket of global currencies although we’ll have to see if the omicron variant impacts that. Its strength has come on the back of comparatively higher interest rates and better economic growth readings. The plans for tapering and rate hikes may be pushed back now, which could bring the dollar back down.</p><p><blockquote>大宗商品方面没什么可做的。原油和汽油价格暴跌，但天然气价格坚守阵地。我怀疑在周五的过度反应之后，能源价格会出现一些均值回归。美元兑一篮子全球货币仍然非常强劲，尽管我们必须看看奥密克戎变量是否会影响这一点。它的走强得益于相对较高的利率和较好的经济增长数据。缩减和加息的计划现在可能会被推迟，这可能会导致美元回落。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Omicron The Catalyst That Ushers In The Next Bear Market?<blockquote>奥密克戎是迎来下一轮熊市的催化剂吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Omicron The Catalyst That Ushers In The Next Bear Market?<blockquote>奥密克戎是迎来下一轮熊市的催化剂吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-11-30 15:34</span>\n</p>\n</h4>\n</header>\n<article>\n<p>There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&amp;P 500 to its largest single day loss since February and the Russell 2000 to its largest single day loss since June of last year. The reveal of a potentially more mutated and more highly contagious version of both the original COVID strain and the delta variant brought investors back to the early days of the pandemic when businesses, schools and other groups were suddenly forced to shut down.</p><p><blockquote>本周金融市场显然只有一个话题。COVID病毒omicron变种的公布让投资者陷入恐慌，并导致标普500创下自2月以来的最大单日跌幅，Russell 2000指数创下自去年6月以来的最大单日跌幅。原始新冠病毒株和德尔塔变异毒株病毒的潜在变异更多、传染性更强的版本的披露，让投资者回到了大流行初期，当时企业、学校和其他团体突然被迫关闭。</blockquote></p><p> Is it going to be as big of a deal as the markets fear it might be? It’s too early to know for sure (although the South African Medical Association seems to be&nbsp;downplaying&nbsp;the severity of it), but global governments appear to be taking no chances. Several countries have shut down their borders to people from South Africa and neighboring countries. New York has already&nbsp;declared&nbsp;a state of emergency despite no reported cases of the omicron variant. Of course, there’s still much to learn about the risk level of this COVID strain, but it’s clear that nerves are a bit frayed.</p><p><blockquote>这会像市场担心的那样重要吗？现在确定还为时过早（尽管南非医学协会似乎淡化了它的严重性），但全球政府似乎没有冒险。几个国家已经对来自南非和邻国的人关闭了边境。尽管没有奥密克戎变种病例的报告，但纽约已经宣布进入紧急状态。当然，关于这种COVID菌株的风险水平还有很多需要了解的，但很明显，神经有点紧张。</blockquote></p><p> In my opinion, Friday’s sharp equity pullback looks like a classic overreaction. Yes, there’s a distinct possibility that it may not be the bottom and equities could sell off further, but given how investors have been prolific dip buyers over the past year and expectations for the taper and future interest rate hikes turned immediately dovish, per the Fed Funds futures market, I think investors will quickly conclude that the omicron variant will likely not be as bad as anticipated and, even if it is, the Fed will quickly step in, whether it’s via a delayed taper or no rate hike until 2023, to support risk asset prices. If I’m going out on a limb, I think there’s a chance the S&amp;P 500 could recapture its all-time high (it’s currently about 2.3% below it) by the end of this week.</p><p><blockquote>在我看来，周五股市的大幅回调看起来像是典型的过度反应。是的，很有可能不是底部，股市可能会进一步抛售，但考虑到投资者在过去一年中一直是多产的逢低买家，以及对缩减购债规模和未来加息的预期立即转向鸽派，根据联邦基金期货市场，我认为投资者很快就会得出结论，奥密克戎的变体可能不会像预期的那么糟糕，即使是这样，美联储也会迅速介入，无论是通过推迟缩减购债规模还是在2023年之前不加息，以支持风险资产价格。如果我冒险的话，我认为标普500有可能在本周末重新夺回历史高点（目前比其低约2.3%）。</blockquote></p><p> Market internals had already been softening leading up to last week. Breadth within the Nasdaq 100 has been getting weaker - 30 of the 100 components have&nbsp;pulled back&nbsp;at least 20%. Small-caps have been underperforming for weeks and leadership has rotated away from cyclicals and back into tech and consumer discretionary. Treasuries are looking strong again and even gold has been seeing some action.</p><p><blockquote>直到上周，市场内部已经走软。纳斯达克100指数的广度一直在减弱——100个成分股中有30个已经回调了至少20%。小盘股几周来表现不佳，领导层已从周期性股票转向科技股和非必需消费品。美国国债看起来再次走强，甚至黄金也出现了一些走势。</blockquote></p><p> Fear is high in the markets right now and that presents opportunity. Keep a level head and watch for panic signs (e.g. the number of articles talking about how stocks could pull back 30% from here) and words from the Fed that hint at what the central bank might do. Remember, in 2020 after the initial bear market, stocks rebounded quickly as soon as the Fed and the government stepped in. If Powell pivots to a more dovish stance, U.S. equities could quickly move higher again.</p><p><blockquote>目前市场上的恐惧情绪很高，这带来了机会。保持冷静的头脑，关注恐慌迹象（例如，谈论股市如何从这里回调30%的文章数量）以及美联储暗示央行可能采取行动的言论。请记住，在最初的熊市之后的2020年，美联储和政府一介入，股市就迅速反弹。如果鲍威尔转向更加鸽派的立场，美国股市可能会迅速再次走高。</blockquote></p><p> Let’s start our weekly review by taking a look at the primary market sectors.</p><p><blockquote>让我们从一级市场板块开始我们的每周回顾。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d87d1ba9c165a777608a551646236565\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Not surprisingly, there’s little short-term strength in equities right now. Communication services remains the worst-looking of the 11 major sectors, but cyclicals are not that far behind. Energy stocks were down 4% on Friday as crude oil prices dropped more than 10%, but still managed to gain more than 1% on the week as a whole. Financials are weaker on falling interest rates, but industrials and materials are similarly well off recent highs.</p><p><blockquote>毫不奇怪，目前股市几乎没有短期走强。通信服务仍然是11个主要行业中最糟糕的，但周期性行业也不甘落后。由于原油价格下跌超过10%，能源股周五下跌4%，但全周仍上涨超过1%。由于利率下降，金融股走软，但工业和材料股同样远低于近期高点。</blockquote></p><p> As I mentioned above, tech and consumer discretionary have been the beneficiaries of rotation trades lately. Tech had become a steady outperformer before last week’s correction, while discretionary stocks have gained but remained volatile. Four of the 11 GICS sectors are now trading below their 50-day moving averages, which could be an indication that short-term momentum has run its course and it may be time for defensives to take over.</p><p><blockquote>正如我上面提到的，科技和非必需消费品最近一直是轮动交易的受益者。在上周的调整之前，科技股一直表现稳定，而非必需股有所上涨，但仍然波动。11个GICS板块中有4个目前交易价格低于50日移动均线，这可能表明短期势头已经结束，可能是时候让防御性板块接手了。</blockquote></p><p> The performance of small-caps, Treasuries and cyclicals point to more conservative positioning even before Friday. Utilities and consumer staples did relatively better as expected, but it’s been a while since either group had an extended run. This week will be telling, I think, in determining where investor risk tolerance is really at. If omicron looks like it will keep drawing out people’s fears, there might be room for defensive sectors to perform relatively well. Keep in mind that it’ll be all about business and social restrictions. If the economic impact is limited mostly to the leisure and travel sectors, the longer-term damage could be minimal.</p><p><blockquote>小盘股、国债和周期性股票的表现表明，即使在周五之前，仓位也会更加保守。公用事业和必需消费品的表现相对好于预期，但这两个行业都已经有一段时间没有长期上涨了。我认为，本周将有助于确定投资者的风险承受能力。如果奥密克戎看起来会继续引起人们的恐惧，那么防御性板块可能还有表现相对较好的空间。请记住，这将是所有关于商业和社会限制。如果经济影响主要限于休闲和旅游部门，那么长期损害可能很小。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/cbc4d98c13f73357d48d25a67a1ed80e\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p><p> Short-term strength has fallen pretty much across the board, but with a few exceptions. Semiconductor stocks had a rough week along with the rest of the tech sector, but they remain one of the best performing groups throughout 2021. Homebuilder stocks continue to build on the strength in the housing, which, despite some stops and starts in sales, demand and commodity prices, been pretty consistent.</p><p><blockquote>短期强度几乎全面下降，但也有少数例外。半导体股与其他科技股一样经历了艰难的一周，但它们仍然是2021年表现最好的股票之一。住宅建筑商股票继续在房地产市场走强的基础上上涨，尽管销售、需求和大宗商品价格出现了一些起起伏伏，但房地产市场却相当稳定。</blockquote></p><p> No surprise that the casino, leisure and recreation stocks are getting hit the hardest. These, of course, are the first to get hit in an environment like this. New travel restrictions are already being put in place and we’re very likely to see even more in the coming weeks. As we’ve seen with New York, there’s been little hesitation so far to put mitigation efforts in place. Oil prices and energy demand forecasts have taken a hit adding to the pressure.</p><p><blockquote>毫不奇怪，赌场、休闲和娱乐股受到的打击最大。当然，在这样的环境中，这些是第一批受到打击的。新的旅行限制已经实施，我们很可能在未来几周看到更多。正如我们在纽约看到的那样，到目前为止，人们毫不犹豫地采取了缓解措施。油价和能源需求预测受到打击，加剧了压力。</blockquote></p><p> No major changes in the communication services sector. We’re still seeing weakness throughout, including the social media stocks, which continue to have a hard time reversing sentiment. The traditional telecoms were virtually changed this past week and could actually become a source of support should prices continue falling here.</p><p><blockquote>通信服务板块无重大变化。我们仍然看到整体疲软，包括社交媒体股票，它们仍然很难扭转市场情绪。传统电信在过去一周几乎发生了变化，如果这里的价格继续下跌，实际上可能会成为支持的来源。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b04029e09b601d3f39d2cfc0be349d00\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Oil prices got hammered last week, which led to 5-6% losses for the explorers and servicers. The broader energy sector did comparatively better, but even clean energy posted a loss of 4% indicating little support across the board. Short-term sentiment for this sector has largely disappeared and the huge returns of earlier this year have long since been forgotten. This will be an especially omicron-dependent sector this week, so expect some above average volatility. Flow numbers show that investors are abandoning ship.</p><p><blockquote>上周油价遭受重创，导致勘探商和服务商损失5-6%。更广泛的能源板块表现相对较好，但即使是清洁能源也下跌了4%，表明几乎没有全面支持。该行业的短期情绪已基本消失，今年早些时候的巨额回报早已被遗忘。本周这将是一个特别依赖奥密克戎的行业，因此预计波动性会高于平均水平。流量数据显示投资者正在弃船。</blockquote></p><p> Just like the leisure sector, the airlines are especially weak here, but there’s really no group within the cyclicals that’s doing OK. The gold &amp; silver miners had a moment in the sun, but with gold prices appearing to have lost their momentum again, they’ve been back on the downswing. Infrastructure stock returns have largely been a function of the passage of the infrastructure bill, but that momentum it also likely to begin fading.</p><p><blockquote>就像休闲行业一样，航空公司在这里尤其疲软，但周期性行业中确实没有一个集团表现良好。黄金和白银矿商度过了一段美好的时光，但随着金价似乎再次失去动力，他们又回到了下跌趋势。基础设施股票的回报在很大程度上取决于基础设施法案的通过，但这种势头也可能开始消退。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4d74ecebe8c9240855b76ea5a23034f4\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Healthcare is starting to look a little, well, healthier again. Most of it looks like it’s due to its defensive sector peers starting to draw a little interest again, but any kind of health-related headlines, such as a new COVID variant, tend to produce at least a modest short-term bounce. Both Moderna and BioNTech, the makers of different COVID vaccines, were both up more than 20% last week alone and that’s making the biotech sector look a little stronger than it is. The&nbsp;<b>SPDR S&amp;P Biotech ETF (XBI)</b>, which equal weights the sector and gives much less weight to those names, was down 4% last week. There is some money moving back into this space, but I don’t think it’s a compelling move just yet.</p><p><blockquote>医疗保健又开始看起来有点，嗯，更健康了。这在很大程度上看起来是由于其防御性行业同行开始再次引起一些兴趣，但任何与健康相关的头条新闻，例如新的新冠病毒变种，往往至少会产生适度的短期反弹。不同新冠疫苗的制造商Moderna和BioNTech仅上周就上涨了20%以上，这使得生物技术行业看起来比实际情况要强一些。The<b>SPDR S&amp;P生物技术ETF(XBI)</b>该指数对该行业的权重相等，但对这些股票的权重要小得多，上周下跌了4%。有一些资金回流到这个领域，但我认为这还不是一个令人信服的举动。</blockquote></p><p> Not much doing on the commodities side. Crude and gasoline prices have plummeted, but natural gas prices have held their ground. I suspect that there’s some mean reversion in energy prices following Friday’s overreaction. The dollar remains very strong against the basket of global currencies although we’ll have to see if the omicron variant impacts that. Its strength has come on the back of comparatively higher interest rates and better economic growth readings. The plans for tapering and rate hikes may be pushed back now, which could bring the dollar back down.</p><p><blockquote>大宗商品方面没什么可做的。原油和汽油价格暴跌，但天然气价格坚守阵地。我怀疑在周五的过度反应之后，能源价格会出现一些均值回归。美元兑一篮子全球货币仍然非常强劲，尽管我们必须看看奥密克戎变量是否会影响这一点。它的走强得益于相对较高的利率和较好的经济增长数据。缩减和加息的计划现在可能会被推迟，这可能会导致美元回落。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/etffocus/market-intelligence/is-omicron-catalyst-that-ushers-in-next-bear-market\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.thestreet.com/etffocus/market-intelligence/is-omicron-catalyst-that-ushers-in-next-bear-market","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171526526","content_text":"There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&P 500 to its largest single day loss since February and the Russell 2000 to its largest single day loss since June of last year. The reveal of a potentially more mutated and more highly contagious version of both the original COVID strain and the delta variant brought investors back to the early days of the pandemic when businesses, schools and other groups were suddenly forced to shut down.\nIs it going to be as big of a deal as the markets fear it might be? It’s too early to know for sure (although the South African Medical Association seems to be downplaying the severity of it), but global governments appear to be taking no chances. Several countries have shut down their borders to people from South Africa and neighboring countries. New York has already declared a state of emergency despite no reported cases of the omicron variant. Of course, there’s still much to learn about the risk level of this COVID strain, but it’s clear that nerves are a bit frayed.\nIn my opinion, Friday’s sharp equity pullback looks like a classic overreaction. Yes, there’s a distinct possibility that it may not be the bottom and equities could sell off further, but given how investors have been prolific dip buyers over the past year and expectations for the taper and future interest rate hikes turned immediately dovish, per the Fed Funds futures market, I think investors will quickly conclude that the omicron variant will likely not be as bad as anticipated and, even if it is, the Fed will quickly step in, whether it’s via a delayed taper or no rate hike until 2023, to support risk asset prices. If I’m going out on a limb, I think there’s a chance the S&P 500 could recapture its all-time high (it’s currently about 2.3% below it) by the end of this week.\nMarket internals had already been softening leading up to last week. Breadth within the Nasdaq 100 has been getting weaker - 30 of the 100 components have pulled back at least 20%. Small-caps have been underperforming for weeks and leadership has rotated away from cyclicals and back into tech and consumer discretionary. Treasuries are looking strong again and even gold has been seeing some action.\nFear is high in the markets right now and that presents opportunity. Keep a level head and watch for panic signs (e.g. the number of articles talking about how stocks could pull back 30% from here) and words from the Fed that hint at what the central bank might do. Remember, in 2020 after the initial bear market, stocks rebounded quickly as soon as the Fed and the government stepped in. If Powell pivots to a more dovish stance, U.S. equities could quickly move higher again.\nLet’s start our weekly review by taking a look at the primary market sectors.\n\nNot surprisingly, there’s little short-term strength in equities right now. Communication services remains the worst-looking of the 11 major sectors, but cyclicals are not that far behind. Energy stocks were down 4% on Friday as crude oil prices dropped more than 10%, but still managed to gain more than 1% on the week as a whole. Financials are weaker on falling interest rates, but industrials and materials are similarly well off recent highs.\nAs I mentioned above, tech and consumer discretionary have been the beneficiaries of rotation trades lately. Tech had become a steady outperformer before last week’s correction, while discretionary stocks have gained but remained volatile. Four of the 11 GICS sectors are now trading below their 50-day moving averages, which could be an indication that short-term momentum has run its course and it may be time for defensives to take over.\nThe performance of small-caps, Treasuries and cyclicals point to more conservative positioning even before Friday. Utilities and consumer staples did relatively better as expected, but it’s been a while since either group had an extended run. This week will be telling, I think, in determining where investor risk tolerance is really at. If omicron looks like it will keep drawing out people’s fears, there might be room for defensive sectors to perform relatively well. Keep in mind that it’ll be all about business and social restrictions. If the economic impact is limited mostly to the leisure and travel sectors, the longer-term damage could be minimal.\n\nShort-term strength has fallen pretty much across the board, but with a few exceptions. Semiconductor stocks had a rough week along with the rest of the tech sector, but they remain one of the best performing groups throughout 2021. Homebuilder stocks continue to build on the strength in the housing, which, despite some stops and starts in sales, demand and commodity prices, been pretty consistent.\nNo surprise that the casino, leisure and recreation stocks are getting hit the hardest. These, of course, are the first to get hit in an environment like this. New travel restrictions are already being put in place and we’re very likely to see even more in the coming weeks. As we’ve seen with New York, there’s been little hesitation so far to put mitigation efforts in place. Oil prices and energy demand forecasts have taken a hit adding to the pressure.\nNo major changes in the communication services sector. We’re still seeing weakness throughout, including the social media stocks, which continue to have a hard time reversing sentiment. The traditional telecoms were virtually changed this past week and could actually become a source of support should prices continue falling here.\n\nOil prices got hammered last week, which led to 5-6% losses for the explorers and servicers. The broader energy sector did comparatively better, but even clean energy posted a loss of 4% indicating little support across the board. Short-term sentiment for this sector has largely disappeared and the huge returns of earlier this year have long since been forgotten. This will be an especially omicron-dependent sector this week, so expect some above average volatility. Flow numbers show that investors are abandoning ship.\nJust like the leisure sector, the airlines are especially weak here, but there’s really no group within the cyclicals that’s doing OK. The gold & silver miners had a moment in the sun, but with gold prices appearing to have lost their momentum again, they’ve been back on the downswing. Infrastructure stock returns have largely been a function of the passage of the infrastructure bill, but that momentum it also likely to begin fading.\n\nHealthcare is starting to look a little, well, healthier again. Most of it looks like it’s due to its defensive sector peers starting to draw a little interest again, but any kind of health-related headlines, such as a new COVID variant, tend to produce at least a modest short-term bounce. Both Moderna and BioNTech, the makers of different COVID vaccines, were both up more than 20% last week alone and that’s making the biotech sector look a little stronger than it is. The SPDR S&P Biotech ETF (XBI), which equal weights the sector and gives much less weight to those names, was down 4% last week. There is some money moving back into this space, but I don’t think it’s a compelling move just yet.\nNot much doing on the commodities side. Crude and gasoline prices have plummeted, but natural gas prices have held their ground. I suspect that there’s some mean reversion in energy prices following Friday’s overreaction. The dollar remains very strong against the basket of global currencies although we’ll have to see if the omicron variant impacts that. Its strength has come on the back of comparatively higher interest rates and better economic growth readings. The plans for tapering and rate hikes may be pushed back now, which could bring the dollar back down.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877689986,"gmtCreate":1637924331182,"gmtModify":1637924331182,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Hooray","listText":"Hooray","text":"Hooray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877689986","repostId":"1190474385","repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=zh_CN&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-26 18:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华","RHHBY":"罗氏控股"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1,"symbols_score_info":{"NVS":0.9,"RHHBY":0.9}},"isVote":1,"tweetType":1,"viewCount":3473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871399532,"gmtCreate":1637023887635,"gmtModify":1637023887694,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Ywah","listText":"Ywah","text":"Ywah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871399532","repostId":"1140879609","repostType":4,"isVote":1,"tweetType":1,"viewCount":4395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873685953,"gmtCreate":1636938238621,"gmtModify":1636938238725,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873685953","repostId":"2183048749","repostType":4,"isVote":1,"tweetType":1,"viewCount":2312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879786919,"gmtCreate":1636773124448,"gmtModify":1636773124448,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Vaccine","listText":"Vaccine","text":"Vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879786919","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":4307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844617599,"gmtCreate":1636422002353,"gmtModify":1636422009758,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh yeah AMD!","listText":"Oh yeah AMD!","text":"Oh yeah AMD!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/844617599","repostId":"2182113779","repostType":4,"isVote":1,"tweetType":1,"viewCount":2681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845842779,"gmtCreate":1636331128796,"gmtModify":1636331128935,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845842779","repostId":"1125924899","repostType":4,"repost":{"id":"1125924899","kind":"news","pubTimestamp":1636330179,"share":"https://www.laohu8.com/m/news/1125924899?lang=zh_CN&edition=full","pubTime":"2021-11-08 08:09","market":"sh","language":"en","title":"Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record<blockquote>供应链问题抑制了巴菲特旗下伯克希尔哈撒韦公司的利润；现金创下纪录</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125924899","media":"Reuters","summary":"Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply","content":"<p>Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.</p><p><blockquote>路透11月6日-沃伦·巴菲特的伯克希尔·哈撒韦公司(BRKa.N)周六表示，全球供应链中断限制了其盈利能力，而股价上涨导致其出售部分股票并将现金储备增加至创纪录水平。</blockquote></p><p> Operating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.</p><p><blockquote>营业利润增长18%，但未达到分析师预期，因为冠状病毒德尔塔变异毒株引发的COVID-19病例死灰复燃导致商品短缺并抑制了消费者支出，而飓风艾达和欧洲洪水造成的损失增加了Geico汽车保险公司和其他保险单位的承保损失。</blockquote></p><p> Net income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).</p><p><blockquote>与此同时，净利润下降了66%，反映出苹果(AAPL.O)和$Bank of America Corp(BAC-N)$(BAC.N)等股票的收益下降。</blockquote></p><p> Berkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.</p><p><blockquote>伯克希尔在第三季度回购了76亿美元的自有股票，今年回购了202亿美元，因为股市上涨使得收购整个公司的成本越来越高。</blockquote></p><p> The buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.</p><p><blockquote>此次回购似乎在10月份仍在继续，这表明91岁的亿万富翁巴菲特认为自己位于内布拉斯加州奥马哈的企业集团具有更大的价值，该集团的业务包括BNSF铁路和同名能源部门。</blockquote></p><p> \"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"</p><p><blockquote>CFRA Research分析师凯茜·塞弗特(Cathy Seifert)表示：“最大的室内游戏之一是，伯克希尔哈撒韦的下一项重大收购是什么。”对伯克希尔哈撒韦给予“持有”评级。“我想我们刚刚看到了：它回购了200亿美元的自己的股票。”</blockquote></p><p> Berkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.</p><p><blockquote>伯克希尔也是股票的净卖家，本季度卖出的股票比买入的多了约20亿美元。截至9月底，该公司拥有1,492亿美元现金及等价物。</blockquote></p><p> \"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones &amp; Co analyst who rates Berkshire a \"buy.\"</p><p><blockquote>爱德华·琼斯公司(Edward Jones&amp;Co)分析师吉姆·沙纳汉(Jim Shanahan)表示：“我确实希望会有更多回购，因为没有太多证据表明资本正在发挥作用。”他将伯克希尔评级为“买入”。</blockquote></p><p> DISRUPTIONS</p><p><blockquote>中断</blockquote></p><p> Third-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.</p><p><blockquote>第三季度营业利润从去年同期的54.8亿美元（约合每股3488美元）升至64.7亿美元（约合每股4331美元）。</blockquote></p><p> Analysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.</p><p><blockquote>根据Refinitiv I/B/E/S的数据，分析师平均预测为每股4,493美元。</blockquote></p><p> Net income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.</p><p><blockquote>净利润从301亿美元降至103亿美元，即每股A股6882美元。巴菲特认为，净利润的巨大季度波动通常毫无意义，是他无法控制的会计规则造成的。</blockquote></p><p> Berkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.</p><p><blockquote>伯克希尔表示，供应链中断推高了材料和运费的价格，迫使Clayton Homes mobile homes和Acme bricks等企业提高价格，并导致McLane grocery distribution卡车司机短缺。</blockquote></p><p> It said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.</p><p><blockquote>该公司表示，这些中断还大幅减少了其汽车经销商部门的新车销量，并增加了其消费品业务的成本，尽管Forest River房车、Brooks跑鞋和金霸王电池的利润正在上升。</blockquote></p><p> In part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.</p><p><blockquote>部分由于达美航空和劳动力短缺造成的干扰，根据政府的预先估计，美国第三季度国内生产总值年化增长率为2%，低于第二季度的6.7%。</blockquote></p><p> \"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo &amp; Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.</p><p><blockquote>宾夕法尼亚州兰开斯特Gardner Russo&amp;Quinn合伙人汤姆·鲁索(Tom Russo)表示：“供应链造成了瓶颈，不可避免地会影响伯克希尔铁路的负载，并导致其住房业务出现短缺。”该公司自1982年以来一直持有伯克希尔股票。</blockquote></p><p> CATASTROPHE LOSSES</p><p><blockquote>灾害损失</blockquote></p><p> Results reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.</p><p><blockquote>结果反映了分析师沙纳汉所说的“极高”的22亿美元巨灾损失，主要来自Ida和洪水，尽管其他保险公司也遭受了巨额损失。</blockquote></p><p> Geico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.</p><p><blockquote>仅Geico就因承保损失2.89亿美元，受到Ida和车祸增加的影响。</blockquote></p><p> In contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.</p><p><blockquote>相比之下，BNSF的利润增长了14%，达到15.4亿美元，因为工业品和煤炭产量的增加抵消了谷物出口的下降。</blockquote></p><p> Buffett's failure to buy more stocks and companies has disappointed some investors and analysts.</p><p><blockquote>巴菲特未能买入更多股票和公司，令一些投资者和分析师感到失望。</blockquote></p><p> It stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.</p><p><blockquote>这部分源于让私营公司上市的特殊目的收购公司（SPAC）如何推高收购目标的价格。</blockquote></p><p> \"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.</p><p><blockquote>“这是一个杀手，”巴菲特在5月1日的伯克希尔年会上说道。</blockquote></p><p> CFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.</p><p><blockquote>CFRA Research分析师塞弗特表示，伯克希尔不会永远袖手旁观，可能会在2022年着眼于收购其长期青睐的行业，包括工业和消费必需品。</blockquote></p><p> \"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, <a href=\"https://laohu8.com/S/AONE.U\">one</a> can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.</p><p><blockquote>“鉴于精密铸件和卡夫亨氏等备受瞩目的失误数量，<a href=\"https://laohu8.com/S/AONE.U\">一</a>我可以理解伯克希尔的一些沉默，”她说，指的是这家飞机零部件制造商和食品公司。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record<blockquote>供应链问题抑制了巴菲特旗下伯克希尔哈撒韦公司的利润；现金创下纪录</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record<blockquote>供应链问题抑制了巴菲特旗下伯克希尔哈撒韦公司的利润；现金创下纪录</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-08 08:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.</p><p><blockquote>路透11月6日-沃伦·巴菲特的伯克希尔·哈撒韦公司(BRKa.N)周六表示，全球供应链中断限制了其盈利能力，而股价上涨导致其出售部分股票并将现金储备增加至创纪录水平。</blockquote></p><p> Operating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.</p><p><blockquote>营业利润增长18%，但未达到分析师预期，因为冠状病毒德尔塔变异毒株引发的COVID-19病例死灰复燃导致商品短缺并抑制了消费者支出，而飓风艾达和欧洲洪水造成的损失增加了Geico汽车保险公司和其他保险单位的承保损失。</blockquote></p><p> Net income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).</p><p><blockquote>与此同时，净利润下降了66%，反映出苹果(AAPL.O)和$Bank of America Corp(BAC-N)$(BAC.N)等股票的收益下降。</blockquote></p><p> Berkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.</p><p><blockquote>伯克希尔在第三季度回购了76亿美元的自有股票，今年回购了202亿美元，因为股市上涨使得收购整个公司的成本越来越高。</blockquote></p><p> The buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.</p><p><blockquote>此次回购似乎在10月份仍在继续，这表明91岁的亿万富翁巴菲特认为自己位于内布拉斯加州奥马哈的企业集团具有更大的价值，该集团的业务包括BNSF铁路和同名能源部门。</blockquote></p><p> \"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"</p><p><blockquote>CFRA Research分析师凯茜·塞弗特(Cathy Seifert)表示：“最大的室内游戏之一是，伯克希尔哈撒韦的下一项重大收购是什么。”对伯克希尔哈撒韦给予“持有”评级。“我想我们刚刚看到了：它回购了200亿美元的自己的股票。”</blockquote></p><p> Berkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.</p><p><blockquote>伯克希尔也是股票的净卖家，本季度卖出的股票比买入的多了约20亿美元。截至9月底，该公司拥有1,492亿美元现金及等价物。</blockquote></p><p> \"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones &amp; Co analyst who rates Berkshire a \"buy.\"</p><p><blockquote>爱德华·琼斯公司(Edward Jones&amp;Co)分析师吉姆·沙纳汉(Jim Shanahan)表示：“我确实希望会有更多回购，因为没有太多证据表明资本正在发挥作用。”他将伯克希尔评级为“买入”。</blockquote></p><p> DISRUPTIONS</p><p><blockquote>中断</blockquote></p><p> Third-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.</p><p><blockquote>第三季度营业利润从去年同期的54.8亿美元（约合每股3488美元）升至64.7亿美元（约合每股4331美元）。</blockquote></p><p> Analysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.</p><p><blockquote>根据Refinitiv I/B/E/S的数据，分析师平均预测为每股4,493美元。</blockquote></p><p> Net income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.</p><p><blockquote>净利润从301亿美元降至103亿美元，即每股A股6882美元。巴菲特认为，净利润的巨大季度波动通常毫无意义，是他无法控制的会计规则造成的。</blockquote></p><p> Berkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.</p><p><blockquote>伯克希尔表示，供应链中断推高了材料和运费的价格，迫使Clayton Homes mobile homes和Acme bricks等企业提高价格，并导致McLane grocery distribution卡车司机短缺。</blockquote></p><p> It said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.</p><p><blockquote>该公司表示，这些中断还大幅减少了其汽车经销商部门的新车销量，并增加了其消费品业务的成本，尽管Forest River房车、Brooks跑鞋和金霸王电池的利润正在上升。</blockquote></p><p> In part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.</p><p><blockquote>部分由于达美航空和劳动力短缺造成的干扰，根据政府的预先估计，美国第三季度国内生产总值年化增长率为2%，低于第二季度的6.7%。</blockquote></p><p> \"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo &amp; Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.</p><p><blockquote>宾夕法尼亚州兰开斯特Gardner Russo&amp;Quinn合伙人汤姆·鲁索(Tom Russo)表示：“供应链造成了瓶颈，不可避免地会影响伯克希尔铁路的负载，并导致其住房业务出现短缺。”该公司自1982年以来一直持有伯克希尔股票。</blockquote></p><p> CATASTROPHE LOSSES</p><p><blockquote>灾害损失</blockquote></p><p> Results reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.</p><p><blockquote>结果反映了分析师沙纳汉所说的“极高”的22亿美元巨灾损失，主要来自Ida和洪水，尽管其他保险公司也遭受了巨额损失。</blockquote></p><p> Geico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.</p><p><blockquote>仅Geico就因承保损失2.89亿美元，受到Ida和车祸增加的影响。</blockquote></p><p> In contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.</p><p><blockquote>相比之下，BNSF的利润增长了14%，达到15.4亿美元，因为工业品和煤炭产量的增加抵消了谷物出口的下降。</blockquote></p><p> Buffett's failure to buy more stocks and companies has disappointed some investors and analysts.</p><p><blockquote>巴菲特未能买入更多股票和公司，令一些投资者和分析师感到失望。</blockquote></p><p> It stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.</p><p><blockquote>这部分源于让私营公司上市的特殊目的收购公司（SPAC）如何推高收购目标的价格。</blockquote></p><p> \"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.</p><p><blockquote>“这是一个杀手，”巴菲特在5月1日的伯克希尔年会上说道。</blockquote></p><p> CFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.</p><p><blockquote>CFRA Research分析师塞弗特表示，伯克希尔不会永远袖手旁观，可能会在2022年着眼于收购其长期青睐的行业，包括工业和消费必需品。</blockquote></p><p> \"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, <a href=\"https://laohu8.com/S/AONE.U\">one</a> can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.</p><p><blockquote>“鉴于精密铸件和卡夫亨氏等备受瞩目的失误数量，<a href=\"https://laohu8.com/S/AONE.U\">一</a>我可以理解伯克希尔的一些沉默，”她说，指的是这家飞机零部件制造商和食品公司。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125924899","content_text":"Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.\nOperating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.\nNet income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).\nBerkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.\nThe buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.\n\"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"\nBerkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.\n\"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones & Co analyst who rates Berkshire a \"buy.\"\nDISRUPTIONS\nThird-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.\nAnalysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.\nNet income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.\nBerkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.\nIt said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.\nIn part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.\n\"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo & Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.\nCATASTROPHE LOSSES\nResults reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.\nGeico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.\nIn contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.\nBuffett's failure to buy more stocks and companies has disappointed some investors and analysts.\nIt stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.\n\"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.\nCFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.\n\"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, one can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.","news_type":1,"symbols_score_info":{"BRK.B":0.9,"BRK.A":0.9}},"isVote":1,"tweetType":1,"viewCount":2631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842838016,"gmtCreate":1636160870694,"gmtModify":1636160948481,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Cheers","listText":"Cheers","text":"Cheers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842838016","repostId":"1173813098","repostType":4,"isVote":1,"tweetType":1,"viewCount":2943,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857460294,"gmtCreate":1635555751407,"gmtModify":1635555751407,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857460294","repostId":"2179240376","repostType":4,"isVote":1,"tweetType":1,"viewCount":806,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854245705,"gmtCreate":1635465395781,"gmtModify":1635465395921,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854245705","repostId":"1147570640","repostType":4,"isVote":1,"tweetType":1,"viewCount":746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855941229,"gmtCreate":1635329421608,"gmtModify":1635329421709,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855941229","repostId":"1130740347","repostType":4,"isVote":1,"tweetType":1,"viewCount":945,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852945165,"gmtCreate":1635237168906,"gmtModify":1635237630982,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Congrats Tiger","listText":"Congrats Tiger","text":"Congrats Tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/852945165","repostId":"1134836974","repostType":4,"repost":{"id":"1134836974","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635235567,"share":"https://www.laohu8.com/m/news/1134836974?lang=zh_CN&edition=full","pubTime":"2021-10-26 16:06","market":"us","language":"en","title":"UP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited<blockquote>老虎证券控股有限公司收购海悦证券有限公司获证监会批准</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134836974","media":"Tiger Newspress","summary":"BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” o","content":"<p>BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.</p><p><blockquote>北京，2021年10月26日(环球通讯社)--专注于全球投资者的领先在线经纪公司老虎证券控股有限公司（纳斯达克：TIGR）（“老虎证券”或“公司”）今天宣布已获香港证券及期货事务监察委员会（“证监会”）批准完成收购Ocean Joy Securities Limited（“OJSL”），该公司是一家获证监会许可从事第一类（证券交易）及第二类（期货合约交易）受规管活动的公司。</blockquote></p><p> The Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.</p><p><blockquote>本公司预期完成收购，并预期于完成后开始于香港经营其经纪业务。</blockquote></p><p> About UP Fintech Holding Limited</p><p><blockquote>关于老虎证券控股有限公司</blockquote></p><p> UP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.</p><p><blockquote>老虎证券控股有限公司是一家专注于全球投资者的领先在线经纪公司。该公司专有的移动和在线交易平台使投资者能够在全球多个交易所交易股票和其他金融工具。该公司通过其“移动优先”战略为客户提供创新的产品和服务以及卓越的用户体验，这使其能够更好地服务和留住现有客户以及吸引新客户。该公司为客户提供全面的经纪和增值服务，包括交易订单的下达和执行、保证金融资、IPO认购、员工持股计划管理、投资者教育、社区讨论和客户支持。该公司的专有基础设施和先进技术能够支持跨多种货币、多个市场、多种产品、多个执行场所和多个清算所的交易。</blockquote></p><p> For more information on the Company, please visit：<a href=\"https://ir.itiger.com\" target=\"_blank\">https://ir.itiger.com</a></p><p><blockquote>有关公司的更多信息，请访问：<a href=\"https://ir.itiger.com\" target=\"_blank\">https://ir.itiger.com</a></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited<blockquote>老虎证券控股有限公司收购海悦证券有限公司获证监会批准</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUP Fintech Holding Limited Receives Approval from SFC of Acquisition of Ocean Joy Securities Limited<blockquote>老虎证券控股有限公司收购海悦证券有限公司获证监会批准</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-26 16:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.</p><p><blockquote>北京，2021年10月26日(环球通讯社)--专注于全球投资者的领先在线经纪公司老虎证券控股有限公司（纳斯达克：TIGR）（“老虎证券”或“公司”）今天宣布已获香港证券及期货事务监察委员会（“证监会”）批准完成收购Ocean Joy Securities Limited（“OJSL”），该公司是一家获证监会许可从事第一类（证券交易）及第二类（期货合约交易）受规管活动的公司。</blockquote></p><p> The Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.</p><p><blockquote>本公司预期完成收购，并预期于完成后开始于香港经营其经纪业务。</blockquote></p><p> About UP Fintech Holding Limited</p><p><blockquote>关于老虎证券控股有限公司</blockquote></p><p> UP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.</p><p><blockquote>老虎证券控股有限公司是一家专注于全球投资者的领先在线经纪公司。该公司专有的移动和在线交易平台使投资者能够在全球多个交易所交易股票和其他金融工具。该公司通过其“移动优先”战略为客户提供创新的产品和服务以及卓越的用户体验，这使其能够更好地服务和留住现有客户以及吸引新客户。该公司为客户提供全面的经纪和增值服务，包括交易订单的下达和执行、保证金融资、IPO认购、员工持股计划管理、投资者教育、社区讨论和客户支持。该公司的专有基础设施和先进技术能够支持跨多种货币、多个市场、多种产品、多个执行场所和多个清算所的交易。</blockquote></p><p> For more information on the Company, please visit：<a href=\"https://ir.itiger.com\" target=\"_blank\">https://ir.itiger.com</a></p><p><blockquote>有关公司的更多信息，请访问：<a href=\"https://ir.itiger.com\" target=\"_blank\">https://ir.itiger.com</a></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TIGR":"老虎证券"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134836974","content_text":"BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that it has received approval from The Hong Kong Securities and Futures Commission (\"SFC\") to complete the acquisition of Ocean Joy Securities Limited (\"OJSL\"), a firm licensed with the SFC for Type I (Dealing in Securities) and Type II (Dealing in Futures Contracts) regulated activities.\nThe Company expects to complete the acquisition and, upon completion, expects to start to operate its brokerage business in Hong Kong.\nAbout UP Fintech Holding Limited\nUP Fintech Holding Limited is a leading online brokerage firm focusing on global investors. The Company’s proprietary mobile and online trading platform enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The Company offers innovative products and services as well as a superior user experience to customers through its “mobile first” strategy, which enables it to better serve and retain current customers as well as attract new ones. The Company offers customers comprehensive brokerage and value-added services, including trade order placement and execution, margin financing, IPO subscription, ESOP management, investor education, community discussion and customer support. The Company’s proprietary infrastructure and advanced technology are able to support trades across multiple currencies, multiple markets, multiple products, multiple execution venues and multiple clearinghouses.\nFor more information on the Company, please visit：https://ir.itiger.com","news_type":1,"symbols_score_info":{"TIGR":0.9}},"isVote":1,"tweetType":1,"viewCount":821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852945931,"gmtCreate":1635237133809,"gmtModify":1635237630604,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh wow nice","listText":"Oh wow nice","text":"Oh wow nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/852945931","repostId":"1111450640","repostType":4,"isVote":1,"tweetType":1,"viewCount":599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822140419,"gmtCreate":1634105603856,"gmtModify":1634105604027,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"#hodl to the moon&nbsp;","listText":"#hodl to the moon&nbsp;","text":"#hodl to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822140419","repostId":"1107758297","repostType":4,"repost":{"id":"1107758297","kind":"news","pubTimestamp":1634088266,"share":"https://www.laohu8.com/m/news/1107758297?lang=zh_CN&edition=full","pubTime":"2021-10-13 09:24","market":"us","language":"en","title":"What Is A Short Squeeze And What Is Going On In GameStop, AMC<blockquote>什么是轧空以及AMC游戏驿站正在发生什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107758297","media":"investors","summary":"What is it that can put a stock on a meteoric rise? This year, we have seen a number of stocks make ","content":"<p>What is it that can put a stock on a meteoric rise? This year, we have seen a number of stocks make truly staggering jumps, doubling in price on consecutive days. There are several factors that are contributing to these gargantuan moves, but one is surely the classic short squeeze.</p><p><blockquote>是什么能让一只股票迅速上涨？今年，我们看到许多股票实现了真正惊人的上涨，价格连续几天翻倍。有几个因素导致了这些巨大的波动，但其中之一肯定是经典的轧空。</blockquote></p><p> While there are some new factors at play in the markets today, the short squeeze has been around as long as shorting stock.</p><p><blockquote>尽管当今市场上有一些新因素在起作用，但空头挤压与做空股票一样长期存在。</blockquote></p><p> What Is A Short Squeeze</p><p><blockquote>什么是轧空</blockquote></p><p> Here is how the short squeeze works. If traders think a stock's price is going lower, they canshort the stock. They borrow shares and sell them, with the intent of buying them back at lower prices.</p><p><blockquote>以下是轧空的工作原理。如果交易者认为股票价格正在下跌，他们可以做空该股票。他们借入股票并出售，目的是以更低的价格回购。</blockquote></p><p> This is mostly done by institutional investors, like hedge funds, given the risks and the margin required.</p><p><blockquote>考虑到风险和所需保证金，这主要是由对冲基金等机构投资者完成的。</blockquote></p><p> And there are big risks. Stocks can theoretically go up infinitely. So a&nbsp;trader who is short&nbsp;can face theoretically infinite losses.</p><p><blockquote>而且存在很大的风险。股票理论上可以无限上涨。因此，做空的交易者理论上可能会面临无限的损失。</blockquote></p><p> Some stocks attract&nbsp;very high short interest, which can be viewed as the amount of shares sold short as a percentage of float, or how much stock has been issued that is available for trading.</p><p><blockquote>有些股票吸引了非常高的空头兴趣，这可以被视为卖空的股票数量占流通量的百分比，或者已发行的可供交易的股票数量。</blockquote></p><p> The problem comes if the stock prices starts to rise quickly. Those that are short the stock will likely receive a margin call. They either have to put more money up to secure their position or close their positions.</p><p><blockquote>如果股价开始快速上涨，问题就来了。那些做空该股票的人可能会获得保证金看涨期权。他们要么必须投入更多资金来确保自己的头寸，要么平仓。</blockquote></p><p> If they choose to — or are forced to — close their position, they are buying the stock to close out their position. This can push the price higher and force other short sellers to do the same. This creates a reinforcing loop of buying and pushing the price higher. This is the short squeeze, as those short the market get \"squeezed\" out.</p><p><blockquote>如果他们选择——或被迫——平仓，他们就是在购买股票来平仓。这可能会推高价格并迫使其他卖空者也这样做。这就形成了一个购买和推高价格的强化循环。这就是空头挤压，因为那些做空市场的人会被“挤出”出去。</blockquote></p><p> Short Squeeze Stocks: GME</p><p><blockquote>轧空股票：GME</blockquote></p><p> This is definitely part of what was happening in&nbsp;<b>GameStop</b>(GME) stock. In August of 2020, GME stock was trading for around 4.</p><p><blockquote>这绝对是发生在<b>游戏驿站</b>（GME）股票。2020年8月，GME股票交易价格约为4。</blockquote></p><p> Shares steadily climbed higher to close out 2020 just under 20 on the back of some big name investors taking stakes in the company. This attracted the short sellers, notably some big hedge funds. Then, on Jan. 13, the stock jumped to hit a high of almost 40 on huge volume.</p><p><blockquote>在一些知名投资者入股该公司的背景下，该公司股价稳步攀升，2020年收盘价略低于20点。这吸引了卖空者，尤其是一些大型对冲基金。然后，在1月13日，该股在成交量巨大的情况下跃升至近40点的高点。</blockquote></p><p> That was surely the start of the short squeeze. That 40 level held for about a week. On Jan. 22, the stock jumped again, trading above 70 on the biggest volume day up to that point.</p><p><blockquote>这无疑是空头挤压的开始。40的水平持续了大约一周。1月22日，该股再次上涨，在迄今为止成交量最大的一天交易价格突破70美元。</blockquote></p><p> The next day the stock hit a high of almost 160 with similar action the next day. Then on Jan. 27 the stock doubled again, trading up to 380. The Jan. 28 high was 483.</p><p><blockquote>第二天，该股触及近160点的高点，第二天也出现了类似的走势。随后在1月27日，该股再次翻倍，交易价格高达380点。1月28日的高点是483。</blockquote></p><p> While short squeezes are nothing new, this action is unprecedented. The action is certainly partly stock buying by the Reddit group wallstreetbets.</p><p><blockquote>虽然轧空并不是什么新鲜事，但这一行动却是前所未有的。这一行动肯定部分是Reddit组织wallstreetbets购买股票的结果。</blockquote></p><p> And while many are cheering that the little retail traders are beating up the big institutional shorts, it is pretty clear that other institutions are also in on this buying. Stories have popped up about Michael Burry's gains on GME stock and Elon Musk was tweeting about it.</p><p><blockquote>虽然许多人欢呼小型散户交易者击败大型机构空头，但很明显，其他机构也参与了这一购买。有关迈克尔·伯里(Michael Burry)增持GME股票的故事不断涌现，埃隆·马斯克(Elon Musk)也在推特上发布了相关消息。</blockquote></p><p> Hedge Fund Losses</p><p><blockquote>对冲基金损失</blockquote></p><p> There are some big losses in this squeeze.</p><p><blockquote>这次挤压有一些很大的损失。</blockquote></p><p> Two funds in particular have been hard hit. Citron Research and Melvin Capital have reportedly suffered huge losses.</p><p><blockquote>两只基金尤其受到重创。据报道，Citron Research和Melvin Capital遭受了巨大损失。</blockquote></p><p> Melvin is down 30% in 2021 on the back of a GME stock short position. It turned to Steven Cohen of Point72 Capital and Chicago-based Citadel to bail it out.</p><p><blockquote>由于GME股票空头头寸，梅尔文在2021年下跌了30%。它向Point72 Capital的史蒂文·科恩(Steven Cohen)和芝加哥Citadel寻求救助。</blockquote></p><p> The short squeeze is usually something inflicted by one hedge fund on another.</p><p><blockquote>轧空通常是一个对冲基金对另一个对冲基金造成的。</blockquote></p><p> This is really the first time we have seen such trading instigated by a band of retail traders.</p><p><blockquote>这确实是我们第一次看到由一群散户煽动的此类交易。</blockquote></p><p> Options Trading Is Also A Big Factor</p><p><blockquote>期权交易也是一大因素</blockquote></p><p> Another piece of this story's plot is the fact that much of the trading in GME and other names like&nbsp;<b>AMC Entertainment</b>(AMC) and&nbsp;<b>BlackBerry</b>(BB) is actually taking place in the&nbsp;options market.</p><p><blockquote>这个故事的另一个情节是，GME和其他名称的大部分交易，例如<b>AMC院线</b>（AMC）和<b>黑莓</b>（BB）实际上发生在期权市场。</blockquote></p><p> Bullish call buying instead of buying the stock is attractive here because of the leverage it provides and the fact that the positions are limited risk.</p><p><blockquote>看涨看涨期权买入而不是买入股票在这里很有吸引力，因为它提供了杠杆，而且头寸风险有限。</blockquote></p><p> Calls are contracts that give the right to buy the underlying stock for a given price (strike price) until the expiration date.</p><p><blockquote>评级是赋予在到期日之前以给定价格（执行价格）购买标的股票的权利的合约。</blockquote></p><p> The most that can be lost is the premium paid for the calls.</p><p><blockquote>最多损失的就是为评级支付的保费。</blockquote></p><p> Buying calls requires much less capital, so bigger positions can be taken by small traders.</p><p><blockquote>购买评级所需的资金要少得多，因此小交易者可以持有更大的头寸。</blockquote></p><p> This actually adds to the short squeeze effect.</p><p><blockquote>这实际上增加了空头挤压效应。</blockquote></p><p> When retail traders buy calls, it is market makers that sell them.</p><p><blockquote>当散户交易者买入评级时，卖出它们的是做市商。</blockquote></p><p> The market makers don't want the risk of being short calls, so they do something called delta hedging.</p><p><blockquote>做市商不想冒做空评级的风险，所以他们做了一种叫做delta对冲的事情。</blockquote></p><p> What Is Delta Hedging, And Why It Matters In A Short Squeeze</p><p><blockquote>什么是Delta对冲，以及为什么它在轧空中很重要</blockquote></p><p> Delta hedging calls requires the market makers to buy stock. And because of the nature of calls, when the price of the underlying stock goes up, the market makers have to buy more stock to stay hedged.</p><p><blockquote>Delta对冲评级要求做市商购买股票。由于评级的性质，当标的股票价格上涨时，做市商必须购买更多股票以保持对冲。</blockquote></p><p> We might call this the call option squeeze.</p><p><blockquote>我们可能会看涨期权这是看涨期权期权挤压。</blockquote></p><p> The problem is that these moves are not based on any fundamental changes in the stocks.</p><p><blockquote>问题是，这些举措并不是基于股票的任何根本性变化。</blockquote></p><p> Not much has changed for GME stock since it was a $4 stock, and certainly not since it was a $16 stock.</p><p><blockquote>自从GME股票是4美元的股票以来，它没有太大变化，当然自从它是16美元的股票以来也没有太大变化。</blockquote></p><p></p><p> Brokerage firms are very concerned about the volatility of these moves, as they know they may face losses if customers can't cover positions. They started limiting the positions that can be taken in some of these names.</p><p><blockquote>经纪公司非常担心这些走势的波动性，因为他们知道，如果客户无法补仓，他们可能会面临损失。他们开始限制其中一些名字的位置。</blockquote></p><p> That news came on Jan. 28, which saw GameStop stock price range from over 500 to below 115.</p><p><blockquote>这一消息是在1月28日发布的，当时游戏驿站股价从500多点波动到115点以下。</blockquote></p><p> This is a trade you wanted to watch out for. While some hedge funds were hurt and some retail traders made fortunes — at least on paper — this still may end badly.</p><p><blockquote>这是你想要小心的交易。尽管一些对冲基金受到了伤害，一些散户交易者赚了钱——至少在纸面上——但这仍然可能以糟糕的结局告终。</blockquote></p><p> The helium holding these stocks up would not last forever.</p><p><blockquote>支撑这些库存的氦气不会永远持续下去。</blockquote></p><p></p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is A Short Squeeze And What Is Going On In GameStop, AMC<blockquote>什么是轧空以及AMC游戏驿站正在发生什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is A Short Squeeze And What Is Going On In GameStop, AMC<blockquote>什么是轧空以及AMC游戏驿站正在发生什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">investors</strong><span class=\"h-time small\">2021-10-13 09:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What is it that can put a stock on a meteoric rise? This year, we have seen a number of stocks make truly staggering jumps, doubling in price on consecutive days. There are several factors that are contributing to these gargantuan moves, but one is surely the classic short squeeze.</p><p><blockquote>是什么能让一只股票迅速上涨？今年，我们看到许多股票实现了真正惊人的上涨，价格连续几天翻倍。有几个因素导致了这些巨大的波动，但其中之一肯定是经典的轧空。</blockquote></p><p> While there are some new factors at play in the markets today, the short squeeze has been around as long as shorting stock.</p><p><blockquote>尽管当今市场上有一些新因素在起作用，但空头挤压与做空股票一样长期存在。</blockquote></p><p> What Is A Short Squeeze</p><p><blockquote>什么是轧空</blockquote></p><p> Here is how the short squeeze works. If traders think a stock's price is going lower, they canshort the stock. They borrow shares and sell them, with the intent of buying them back at lower prices.</p><p><blockquote>以下是轧空的工作原理。如果交易者认为股票价格正在下跌，他们可以做空该股票。他们借入股票并出售，目的是以更低的价格回购。</blockquote></p><p> This is mostly done by institutional investors, like hedge funds, given the risks and the margin required.</p><p><blockquote>考虑到风险和所需保证金，这主要是由对冲基金等机构投资者完成的。</blockquote></p><p> And there are big risks. Stocks can theoretically go up infinitely. So a&nbsp;trader who is short&nbsp;can face theoretically infinite losses.</p><p><blockquote>而且存在很大的风险。股票理论上可以无限上涨。因此，做空的交易者理论上可能会面临无限的损失。</blockquote></p><p> Some stocks attract&nbsp;very high short interest, which can be viewed as the amount of shares sold short as a percentage of float, or how much stock has been issued that is available for trading.</p><p><blockquote>有些股票吸引了非常高的空头兴趣，这可以被视为卖空的股票数量占流通量的百分比，或者已发行的可供交易的股票数量。</blockquote></p><p> The problem comes if the stock prices starts to rise quickly. Those that are short the stock will likely receive a margin call. They either have to put more money up to secure their position or close their positions.</p><p><blockquote>如果股价开始快速上涨，问题就来了。那些做空该股票的人可能会获得保证金看涨期权。他们要么必须投入更多资金来确保自己的头寸，要么平仓。</blockquote></p><p> If they choose to — or are forced to — close their position, they are buying the stock to close out their position. This can push the price higher and force other short sellers to do the same. This creates a reinforcing loop of buying and pushing the price higher. This is the short squeeze, as those short the market get \"squeezed\" out.</p><p><blockquote>如果他们选择——或被迫——平仓，他们就是在购买股票来平仓。这可能会推高价格并迫使其他卖空者也这样做。这就形成了一个购买和推高价格的强化循环。这就是空头挤压，因为那些做空市场的人会被“挤出”出去。</blockquote></p><p> Short Squeeze Stocks: GME</p><p><blockquote>轧空股票：GME</blockquote></p><p> This is definitely part of what was happening in&nbsp;<b>GameStop</b>(GME) stock. In August of 2020, GME stock was trading for around 4.</p><p><blockquote>这绝对是发生在<b>游戏驿站</b>（GME）股票。2020年8月，GME股票交易价格约为4。</blockquote></p><p> Shares steadily climbed higher to close out 2020 just under 20 on the back of some big name investors taking stakes in the company. This attracted the short sellers, notably some big hedge funds. Then, on Jan. 13, the stock jumped to hit a high of almost 40 on huge volume.</p><p><blockquote>在一些知名投资者入股该公司的背景下，该公司股价稳步攀升，2020年收盘价略低于20点。这吸引了卖空者，尤其是一些大型对冲基金。然后，在1月13日，该股在成交量巨大的情况下跃升至近40点的高点。</blockquote></p><p> That was surely the start of the short squeeze. That 40 level held for about a week. On Jan. 22, the stock jumped again, trading above 70 on the biggest volume day up to that point.</p><p><blockquote>这无疑是空头挤压的开始。40的水平持续了大约一周。1月22日，该股再次上涨，在迄今为止成交量最大的一天交易价格突破70美元。</blockquote></p><p> The next day the stock hit a high of almost 160 with similar action the next day. Then on Jan. 27 the stock doubled again, trading up to 380. The Jan. 28 high was 483.</p><p><blockquote>第二天，该股触及近160点的高点，第二天也出现了类似的走势。随后在1月27日，该股再次翻倍，交易价格高达380点。1月28日的高点是483。</blockquote></p><p> While short squeezes are nothing new, this action is unprecedented. The action is certainly partly stock buying by the Reddit group wallstreetbets.</p><p><blockquote>虽然轧空并不是什么新鲜事，但这一行动却是前所未有的。这一行动肯定部分是Reddit组织wallstreetbets购买股票的结果。</blockquote></p><p> And while many are cheering that the little retail traders are beating up the big institutional shorts, it is pretty clear that other institutions are also in on this buying. Stories have popped up about Michael Burry's gains on GME stock and Elon Musk was tweeting about it.</p><p><blockquote>虽然许多人欢呼小型散户交易者击败大型机构空头，但很明显，其他机构也参与了这一购买。有关迈克尔·伯里(Michael Burry)增持GME股票的故事不断涌现，埃隆·马斯克(Elon Musk)也在推特上发布了相关消息。</blockquote></p><p> Hedge Fund Losses</p><p><blockquote>对冲基金损失</blockquote></p><p> There are some big losses in this squeeze.</p><p><blockquote>这次挤压有一些很大的损失。</blockquote></p><p> Two funds in particular have been hard hit. Citron Research and Melvin Capital have reportedly suffered huge losses.</p><p><blockquote>两只基金尤其受到重创。据报道，Citron Research和Melvin Capital遭受了巨大损失。</blockquote></p><p> Melvin is down 30% in 2021 on the back of a GME stock short position. It turned to Steven Cohen of Point72 Capital and Chicago-based Citadel to bail it out.</p><p><blockquote>由于GME股票空头头寸，梅尔文在2021年下跌了30%。它向Point72 Capital的史蒂文·科恩(Steven Cohen)和芝加哥Citadel寻求救助。</blockquote></p><p> The short squeeze is usually something inflicted by one hedge fund on another.</p><p><blockquote>轧空通常是一个对冲基金对另一个对冲基金造成的。</blockquote></p><p> This is really the first time we have seen such trading instigated by a band of retail traders.</p><p><blockquote>这确实是我们第一次看到由一群散户煽动的此类交易。</blockquote></p><p> Options Trading Is Also A Big Factor</p><p><blockquote>期权交易也是一大因素</blockquote></p><p> Another piece of this story's plot is the fact that much of the trading in GME and other names like&nbsp;<b>AMC Entertainment</b>(AMC) and&nbsp;<b>BlackBerry</b>(BB) is actually taking place in the&nbsp;options market.</p><p><blockquote>这个故事的另一个情节是，GME和其他名称的大部分交易，例如<b>AMC院线</b>（AMC）和<b>黑莓</b>（BB）实际上发生在期权市场。</blockquote></p><p> Bullish call buying instead of buying the stock is attractive here because of the leverage it provides and the fact that the positions are limited risk.</p><p><blockquote>看涨看涨期权买入而不是买入股票在这里很有吸引力，因为它提供了杠杆，而且头寸风险有限。</blockquote></p><p> Calls are contracts that give the right to buy the underlying stock for a given price (strike price) until the expiration date.</p><p><blockquote>评级是赋予在到期日之前以给定价格（执行价格）购买标的股票的权利的合约。</blockquote></p><p> The most that can be lost is the premium paid for the calls.</p><p><blockquote>最多损失的就是为评级支付的保费。</blockquote></p><p> Buying calls requires much less capital, so bigger positions can be taken by small traders.</p><p><blockquote>购买评级所需的资金要少得多，因此小交易者可以持有更大的头寸。</blockquote></p><p> This actually adds to the short squeeze effect.</p><p><blockquote>这实际上增加了空头挤压效应。</blockquote></p><p> When retail traders buy calls, it is market makers that sell them.</p><p><blockquote>当散户交易者买入评级时，卖出它们的是做市商。</blockquote></p><p> The market makers don't want the risk of being short calls, so they do something called delta hedging.</p><p><blockquote>做市商不想冒做空评级的风险，所以他们做了一种叫做delta对冲的事情。</blockquote></p><p> What Is Delta Hedging, And Why It Matters In A Short Squeeze</p><p><blockquote>什么是Delta对冲，以及为什么它在轧空中很重要</blockquote></p><p> Delta hedging calls requires the market makers to buy stock. And because of the nature of calls, when the price of the underlying stock goes up, the market makers have to buy more stock to stay hedged.</p><p><blockquote>Delta对冲评级要求做市商购买股票。由于评级的性质，当标的股票价格上涨时，做市商必须购买更多股票以保持对冲。</blockquote></p><p> We might call this the call option squeeze.</p><p><blockquote>我们可能会看涨期权这是看涨期权期权挤压。</blockquote></p><p> The problem is that these moves are not based on any fundamental changes in the stocks.</p><p><blockquote>问题是，这些举措并不是基于股票的任何根本性变化。</blockquote></p><p> Not much has changed for GME stock since it was a $4 stock, and certainly not since it was a $16 stock.</p><p><blockquote>自从GME股票是4美元的股票以来，它没有太大变化，当然自从它是16美元的股票以来也没有太大变化。</blockquote></p><p></p><p> Brokerage firms are very concerned about the volatility of these moves, as they know they may face losses if customers can't cover positions. They started limiting the positions that can be taken in some of these names.</p><p><blockquote>经纪公司非常担心这些走势的波动性，因为他们知道，如果客户无法补仓，他们可能会面临损失。他们开始限制其中一些名字的位置。</blockquote></p><p> That news came on Jan. 28, which saw GameStop stock price range from over 500 to below 115.</p><p><blockquote>这一消息是在1月28日发布的，当时游戏驿站股价从500多点波动到115点以下。</blockquote></p><p> This is a trade you wanted to watch out for. While some hedge funds were hurt and some retail traders made fortunes — at least on paper — this still may end badly.</p><p><blockquote>这是你想要小心的交易。尽管一些对冲基金受到了伤害，一些散户交易者赚了钱——至少在纸面上——但这仍然可能以糟糕的结局告终。</blockquote></p><p> The helium holding these stocks up would not last forever.</p><p><blockquote>支撑这些库存的氦气不会永远持续下去。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.investors.com/how-to-invest/investors-corner/short-squeeze/?src=A00220\">investors</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","GME":"游戏驿站"},"source_url":"https://www.investors.com/how-to-invest/investors-corner/short-squeeze/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107758297","content_text":"What is it that can put a stock on a meteoric rise? This year, we have seen a number of stocks make truly staggering jumps, doubling in price on consecutive days. There are several factors that are contributing to these gargantuan moves, but one is surely the classic short squeeze.\nWhile there are some new factors at play in the markets today, the short squeeze has been around as long as shorting stock.\nWhat Is A Short Squeeze\nHere is how the short squeeze works. If traders think a stock's price is going lower, they canshort the stock. They borrow shares and sell them, with the intent of buying them back at lower prices.\nThis is mostly done by institutional investors, like hedge funds, given the risks and the margin required.\nAnd there are big risks. Stocks can theoretically go up infinitely. So a trader who is short can face theoretically infinite losses.\nSome stocks attract very high short interest, which can be viewed as the amount of shares sold short as a percentage of float, or how much stock has been issued that is available for trading.\nThe problem comes if the stock prices starts to rise quickly. Those that are short the stock will likely receive a margin call. They either have to put more money up to secure their position or close their positions.\nIf they choose to — or are forced to — close their position, they are buying the stock to close out their position. This can push the price higher and force other short sellers to do the same. This creates a reinforcing loop of buying and pushing the price higher. This is the short squeeze, as those short the market get \"squeezed\" out.\nShort Squeeze Stocks: GME\nThis is definitely part of what was happening in GameStop(GME) stock. In August of 2020, GME stock was trading for around 4.\nShares steadily climbed higher to close out 2020 just under 20 on the back of some big name investors taking stakes in the company. This attracted the short sellers, notably some big hedge funds. Then, on Jan. 13, the stock jumped to hit a high of almost 40 on huge volume.\nThat was surely the start of the short squeeze. That 40 level held for about a week. On Jan. 22, the stock jumped again, trading above 70 on the biggest volume day up to that point.\nThe next day the stock hit a high of almost 160 with similar action the next day. Then on Jan. 27 the stock doubled again, trading up to 380. The Jan. 28 high was 483.\nWhile short squeezes are nothing new, this action is unprecedented. The action is certainly partly stock buying by the Reddit group wallstreetbets.\nAnd while many are cheering that the little retail traders are beating up the big institutional shorts, it is pretty clear that other institutions are also in on this buying. Stories have popped up about Michael Burry's gains on GME stock and Elon Musk was tweeting about it.\nHedge Fund Losses\nThere are some big losses in this squeeze.\nTwo funds in particular have been hard hit. Citron Research and Melvin Capital have reportedly suffered huge losses.\nMelvin is down 30% in 2021 on the back of a GME stock short position. It turned to Steven Cohen of Point72 Capital and Chicago-based Citadel to bail it out.\nThe short squeeze is usually something inflicted by one hedge fund on another.\nThis is really the first time we have seen such trading instigated by a band of retail traders.\nOptions Trading Is Also A Big Factor\nAnother piece of this story's plot is the fact that much of the trading in GME and other names like AMC Entertainment(AMC) and BlackBerry(BB) is actually taking place in the options market.\nBullish call buying instead of buying the stock is attractive here because of the leverage it provides and the fact that the positions are limited risk.\nCalls are contracts that give the right to buy the underlying stock for a given price (strike price) until the expiration date.\nThe most that can be lost is the premium paid for the calls.\nBuying calls requires much less capital, so bigger positions can be taken by small traders.\nThis actually adds to the short squeeze effect.\nWhen retail traders buy calls, it is market makers that sell them.\nThe market makers don't want the risk of being short calls, so they do something called delta hedging.\nWhat Is Delta Hedging, And Why It Matters In A Short Squeeze\nDelta hedging calls requires the market makers to buy stock. And because of the nature of calls, when the price of the underlying stock goes up, the market makers have to buy more stock to stay hedged.\nWe might call this the call option squeeze.\nThe problem is that these moves are not based on any fundamental changes in the stocks.\nNot much has changed for GME stock since it was a $4 stock, and certainly not since it was a $16 stock.\nBrokerage firms are very concerned about the volatility of these moves, as they know they may face losses if customers can't cover positions. They started limiting the positions that can be taken in some of these names.\nThat news came on Jan. 28, which saw GameStop stock price range from over 500 to below 115.\nThis is a trade you wanted to watch out for. While some hedge funds were hurt and some retail traders made fortunes — at least on paper — this still may end badly.\nThe helium holding these stocks up would not last forever.","news_type":1,"symbols_score_info":{"AMC":0.9,"GME":0.9}},"isVote":1,"tweetType":1,"viewCount":915,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822924059,"gmtCreate":1634086595328,"gmtModify":1634086595450,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/822924059","repostId":"1116686750","repostType":4,"repost":{"id":"1116686750","kind":"news","pubTimestamp":1634080775,"share":"https://www.laohu8.com/m/news/1116686750?lang=zh_CN&edition=full","pubTime":"2021-10-13 07:19","market":"hk","language":"en","title":"Hong Kong stock exchange delays morning trading session due to typhoon<blockquote>港交所因台风推迟早盘交易时段</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1116686750","media":"forexlive","summary":"HKEX says that with storm signal in effect the session is delayed.\nSecurities, derivates trade delay","content":"<p><div> HKEX says that with storm signal in effect the session is delayed. Securities, derivates trade delayed opening.</p><p><blockquote><div>港交所表示，由于风暴信号生效，会议将推迟。证券、衍生品交易延迟开放。</div></blockquote></p><p>  <a href=\"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012\">网页连接</a></blockquote></p><p></p>","source":"lsy1623168602413","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong stock exchange delays morning trading session due to typhoon<blockquote>港交所因台风推迟早盘交易时段</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong stock exchange delays morning trading session due to typhoon<blockquote>港交所因台风推迟早盘交易时段</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">forexlive</strong><span class=\"h-time small\">2021-10-13 07:19</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> HKEX says that with storm signal in effect the session is delayed. Securities, derivates trade delayed opening.</p><p><blockquote><div>港交所表示，由于风暴信号生效，会议将推迟。证券、衍生品交易延迟开放。</div></blockquote></p><p>  <a href=\"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012\">forexlive</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSCCI":"红筹指数","HSI":"恒生指数","HSTECH":"恒生科技指数","HSCEI":"国企指数"},"source_url":"https://www.forexlive.com/news/!/hong-kong-stock-exchange-delays-morning-trading-session-due-to-typhoon-20211012","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116686750","content_text":"HKEX says that with storm signal in effect the session is delayed.\nSecurities, derivates trade delayed opening.","news_type":1,"symbols_score_info":{"HSTECH":0.9,"HSCEI":0.9,"HSCCI":0.9,"HSI":0.9}},"isVote":1,"tweetType":1,"viewCount":804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829746958,"gmtCreate":1633561981456,"gmtModify":1633561981591,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Wow 1 bill","listText":"Wow 1 bill","text":"Wow 1 bill","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829746958","repostId":"2173494802","repostType":4,"isVote":1,"tweetType":1,"viewCount":757,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829748320,"gmtCreate":1633561954911,"gmtModify":1633561955107,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829748320","repostId":"2173948202","repostType":4,"isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862621009,"gmtCreate":1632876658893,"gmtModify":1632880628446,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Hahah another fud by motley fool&nbsp;","listText":"Hahah another fud by motley fool&nbsp;","text":"Hahah another fud by motley fool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862621009","repostId":"1156652008","repostType":4,"repost":{"id":"1156652008","kind":"news","pubTimestamp":1632875254,"share":"https://www.laohu8.com/m/news/1156652008?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:27","market":"us","language":"en","title":"Why AMC Stock Dropped Tuesday<blockquote>为什么AMC股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156652008","media":"Motley Fool","summary":"The move occurred as the broader market was declining, but the movie theater operator also got some ","content":"<p>  <b>The move occurred as the broader market was declining, but the movie theater operator also got some potentially bad news recently.</b>  <b>What happened</b></p><p><blockquote><b>此举发生在大盘下跌之际，但这家电影院运营商最近也收到了一些潜在的坏消息。</b><b>发生了什么</b></blockquote></p><p> Sharp moves in<b>AMC Entertainment</b>'s(NYSE:AMC)share price are nothing new this year. The meme stock has endured big jumps and steeps drops with seemingly no reason beyond the flow of chatter on social media's investing forums. On Tuesday, the U.S. stock market was trending downward, and shares of the theater operator were too. But there has also been some worrisome news recently about a situation that could impact AMC's future. As of 12:10 p.m. EDT, AMC shares were down about 4.3%.</p><p><blockquote>夏普进入<b>AMC院线</b>（纽约证券交易所股票代码：AMC）的股价今年并不是什么新鲜事。除了社交媒体投资论坛上的喋喋不休之外，迷因股票经历了大幅上涨和暴跌，似乎没有任何原因。周二，美国股市呈下跌趋势，影院运营商的股价也呈下跌趋势。但最近也有一些令人担忧的消息，有关可能影响AMC未来的情况。截至中午12:10美国东部时间，AMC股价下跌约4.3%。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Over the last week, AMC shares are down by almost 6.5%. That drop may have been related to something<b>Walt Disney</b>CEO Bob Chapek said while speaking at the<b>Goldman Sachs</b>Communacopia Conference last Tuesday.</p><p><blockquote>上周，AMC股价下跌近6.5%。那一滴可能与什么有关<b>迪斯尼</b>首席执行官Bob Chapek在<b>高盛</b>上周二的Communacopia会议。</blockquote></p><p> Even on the heels of the successful theater-only release of Disney's latest Marvel blockbuster,<i>Shang-Chi and the Legend of the Ten Rings</i>, Chapek wouldn't commit to continuing that business model past this year. In fact, he stated that Disney would be flexible with film releases, and implied there will be a mix of debuting movies on its Disney+ streaming service along with various windows fortheater showings.</p><p><blockquote>即使在迪士尼最新的漫威大片仅在影院成功上映之后，<i>尚气与十环传说</i>查佩克不会承诺在今年之后继续这种商业模式。事实上，他表示迪士尼将灵活地发行电影，并暗示将在其Disney+流媒体服务上混合首次亮相的电影以及各种影院放映窗口。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Thatis not something AMC shareholders wantto hear. AMC has seen its market cap lifted to $20 billion on the backs of retail traders hoping to profit by punishing short-sellers. But for the company to begin to justify that valuation, the business itself will have to turn around. Moreover, the company needs to pay down the massive debt it took on so it could stay afloat until customers come back to theaters -- assuming they do return in something like their former numbers.</p><p><blockquote>这不是AMC股东想听到的。由于散户交易者希望通过惩罚卖空者来获利，AMC的市值已升至200亿美元。但为了让公司开始证明这一估值的合理性，业务本身必须扭转局面。此外，该公司需要偿还其承担的巨额债务，以便在顾客重返影院之前维持运营——假设他们确实以与以前相同的数量回归。</blockquote></p><p> With Disney failing to commit to releasing movies exclusively in theaters beyond this year, the future of AMC's business remains uncertain. For investors who are paying attention to the outlook for the business, that's another incentive to take profits and move on.</p><p><blockquote>由于迪士尼未能承诺在今年之后在影院独家发行电影，AMC业务的未来仍不确定。对于关注业务前景的投资者来说，这是获利了结并继续前进的另一个动机。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMC Stock Dropped Tuesday<blockquote>为什么AMC股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMC Stock Dropped Tuesday<blockquote>为什么AMC股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-29 08:27</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>The move occurred as the broader market was declining, but the movie theater operator also got some potentially bad news recently.</b>  <b>What happened</b></p><p><blockquote><b>此举发生在大盘下跌之际，但这家电影院运营商最近也收到了一些潜在的坏消息。</b><b>发生了什么</b></blockquote></p><p> Sharp moves in<b>AMC Entertainment</b>'s(NYSE:AMC)share price are nothing new this year. The meme stock has endured big jumps and steeps drops with seemingly no reason beyond the flow of chatter on social media's investing forums. On Tuesday, the U.S. stock market was trending downward, and shares of the theater operator were too. But there has also been some worrisome news recently about a situation that could impact AMC's future. As of 12:10 p.m. EDT, AMC shares were down about 4.3%.</p><p><blockquote>夏普进入<b>AMC院线</b>（纽约证券交易所股票代码：AMC）的股价今年并不是什么新鲜事。除了社交媒体投资论坛上的喋喋不休之外，迷因股票经历了大幅上涨和暴跌，似乎没有任何原因。周二，美国股市呈下跌趋势，影院运营商的股价也呈下跌趋势。但最近也有一些令人担忧的消息，有关可能影响AMC未来的情况。截至中午12:10美国东部时间，AMC股价下跌约4.3%。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Over the last week, AMC shares are down by almost 6.5%. That drop may have been related to something<b>Walt Disney</b>CEO Bob Chapek said while speaking at the<b>Goldman Sachs</b>Communacopia Conference last Tuesday.</p><p><blockquote>上周，AMC股价下跌近6.5%。那一滴可能与什么有关<b>迪斯尼</b>首席执行官Bob Chapek在<b>高盛</b>上周二的Communacopia会议。</blockquote></p><p> Even on the heels of the successful theater-only release of Disney's latest Marvel blockbuster,<i>Shang-Chi and the Legend of the Ten Rings</i>, Chapek wouldn't commit to continuing that business model past this year. In fact, he stated that Disney would be flexible with film releases, and implied there will be a mix of debuting movies on its Disney+ streaming service along with various windows fortheater showings.</p><p><blockquote>即使在迪士尼最新的漫威大片仅在影院成功上映之后，<i>尚气与十环传说</i>查佩克不会承诺在今年之后继续这种商业模式。事实上，他表示迪士尼将灵活地发行电影，并暗示将在其Disney+流媒体服务上混合首次亮相的电影以及各种影院放映窗口。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Thatis not something AMC shareholders wantto hear. AMC has seen its market cap lifted to $20 billion on the backs of retail traders hoping to profit by punishing short-sellers. But for the company to begin to justify that valuation, the business itself will have to turn around. Moreover, the company needs to pay down the massive debt it took on so it could stay afloat until customers come back to theaters -- assuming they do return in something like their former numbers.</p><p><blockquote>这不是AMC股东想听到的。由于散户交易者希望通过惩罚卖空者来获利，AMC的市值已升至200亿美元。但为了让公司开始证明这一估值的合理性，业务本身必须扭转局面。此外，该公司需要偿还其承担的巨额债务，以便在顾客重返影院之前维持运营——假设他们确实以与以前相同的数量回归。</blockquote></p><p> With Disney failing to commit to releasing movies exclusively in theaters beyond this year, the future of AMC's business remains uncertain. For investors who are paying attention to the outlook for the business, that's another incentive to take profits and move on.</p><p><blockquote>由于迪士尼未能承诺在今年之后在影院独家发行电影，AMC业务的未来仍不确定。对于关注业务前景的投资者来说，这是获利了结并继续前进的另一个动机。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-amc-stock-dropped-tuesday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/why-amc-stock-dropped-tuesday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156652008","content_text":"The move occurred as the broader market was declining, but the movie theater operator also got some potentially bad news recently.\n\nWhat happened\nSharp moves inAMC Entertainment's(NYSE:AMC)share price are nothing new this year. The meme stock has endured big jumps and steeps drops with seemingly no reason beyond the flow of chatter on social media's investing forums. On Tuesday, the U.S. stock market was trending downward, and shares of the theater operator were too. But there has also been some worrisome news recently about a situation that could impact AMC's future. As of 12:10 p.m. EDT, AMC shares were down about 4.3%.\nSo what\nOver the last week, AMC shares are down by almost 6.5%. That drop may have been related to somethingWalt DisneyCEO Bob Chapek said while speaking at theGoldman SachsCommunacopia Conference last Tuesday.\nEven on the heels of the successful theater-only release of Disney's latest Marvel blockbuster,Shang-Chi and the Legend of the Ten Rings, Chapek wouldn't commit to continuing that business model past this year. In fact, he stated that Disney would be flexible with film releases, and implied there will be a mix of debuting movies on its Disney+ streaming service along with various windows fortheater showings.\nNow what\nThatis not something AMC shareholders wantto hear. AMC has seen its market cap lifted to $20 billion on the backs of retail traders hoping to profit by punishing short-sellers. But for the company to begin to justify that valuation, the business itself will have to turn around. Moreover, the company needs to pay down the massive debt it took on so it could stay afloat until customers come back to theaters -- assuming they do return in something like their former numbers.\nWith Disney failing to commit to releasing movies exclusively in theaters beyond this year, the future of AMC's business remains uncertain. For investors who are paying attention to the outlook for the business, that's another incentive to take profits and move on.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":844617599,"gmtCreate":1636422002353,"gmtModify":1636422009758,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Oh yeah AMD!","listText":"Oh yeah AMD!","text":"Oh yeah AMD!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/844617599","repostId":"2182113779","repostType":4,"isVote":1,"tweetType":1,"viewCount":2681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":809174997,"gmtCreate":1627355274919,"gmtModify":1631891968235,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Nice leh","listText":"Nice leh","text":"Nice leh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/809174997","repostId":"2154966721","repostType":4,"repost":{"id":"2154966721","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627355035,"share":"https://www.laohu8.com/m/news/2154966721?lang=zh_CN&edition=full","pubTime":"2021-07-27 11:03","market":"us","language":"en","title":"Why These 3 Microsoft Analysts Are Bullish Ahead Of Q4 Results<blockquote>为什么这三位微软分析师在第四季度业绩公布前看好</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2154966721","media":"Benzinga","summary":"Microsoft Corp. (NASDAQ: MSFT) is set to report fourth-quarter earnings following the market close on Tuesday, July 27. In anticipation of this earnings call, analysts at Citi, KeyBanc and Wedbush Securities have provided insight into the company’s market positioning.","content":"<p><b>Microsoft Corp. </b>(NASDAQ:MSFT) is set to report&nbsp;fourth-quarter earnings following the market close on Tuesday, July 27. In anticipation of this earnings call, analysts at Citi, KeyBanc&nbsp;and Wedbush Securities have provided insight into the company’s market positioning.</p><p><blockquote><b>微软公司。</b>（纳斯达克股票代码：MSFT）将于7月27日星期二收盘后公布第四季度收益。为了应对这一盈利看涨期权，花旗、KeyBanc和Wedbush Securities的分析师提供了对该公司市场定位的见解。</blockquote></p><p> The consensus estimates project fourth-quarter EPS of&nbsp;$1.90 and revenue of&nbsp;$44.1&nbsp;billion.</p><p><blockquote>市场普遍预计第四季度每股收益为1.90美元，营收为441亿美元。</blockquote></p><p> <h3>Citi's Take On Microsoft</h3> “Recovering IT budgets, an uptick in expected reseller growth, signs of reacceleration in consumption models and slightly higher PC numbers vs. 3 months ago” have helped analyst Tyler Radke maintain a positive outlook for Microsoft’s fourth-quarter earnings. The analyst did not provide an exact EPS estimate.</p><p><blockquote><h3>花旗对微软的看法</h3>“IT预算的恢复、经销商预期增长的上升、消费模式重新加速的迹象以及PC数量较3个月前略有增加”帮助分析师泰勒·拉德克(Tyler Radke)维持了对微软第四季度盈利的积极展望。该分析师没有提供确切的每股收益估计。</blockquote></p><p> Longer-term, Microsoft remains Citi’s top large-cap play among North American application software, systems software, and interactive home entertainment stocks, the analyst said in a note.</p><p><blockquote>该分析师在一份报告中表示，从长远来看，微软仍然是花旗在北美应用软件、系统软件和互动家庭娱乐股票中排名第一的大盘股。</blockquote></p><p> The analyst maintained a Buy rating and raised the&nbsp;price target from $310 to $378.</p><p><blockquote>该分析师维持买入评级，并将目标价从310美元上调至378美元。</blockquote></p><p> <h3>KeyBanc's Take On Microsoft</h3> Microsoft is becoming increasingly strategically important in the realm of security, cloud migration&nbsp;and digital transformation, said KeyBanc's managing director and senior analyst of enterprise software Michael Turits.</p><p><blockquote><h3>KeyBanc对微软的看法</h3>KeyBanc董事总经理兼企业软件高级分析师Michael Turits表示，微软在安全、云迁移和数字化转型领域变得越来越重要。</blockquote></p><p> According to a survey of IT value-added resellers (VAR), security, Office 365&nbsp;and Azure are the top areas of spending as the world ushers in an enterprise shift to greater adoption of digital technologies, said the analyst.</p><p><blockquote>这位分析师表示，根据对IT增值经销商（VAR）的一项调查，随着世界迎来企业向更多采用数字技术的转变，安全、Office 365和Azure是最大的支出领域。</blockquote></p><p> The VAR survey additionally highlighted that Microsoft’s products rank highly against competitors, from dev-ops solutions such as GitHub to cloud solutions with Azure to security offerings,&nbsp;which surpassed Okta/Auth0, he said.</p><p><blockquote>他说，VAR调查还强调，微软的产品在竞争对手中排名很高，从GitHub等开发运营解决方案到Azure的云解决方案，再到安全产品，这些产品都超过了Okta/Auth0。</blockquote></p><p> The analyst reiterated an Overweight rating and increased the&nbsp;price target from $305 to $330.</p><p><blockquote>该分析师重申了跑赢大盘评级，并将目标价从305美元上调至330美元。</blockquote></p><p> <h3>Wedbush's Take On Microsoft</h3> Analyst Daniel Ives is expecting a “beat and raise” from Microsoft on&nbsp;earnings and guidance Tuesday.</p><p><blockquote><h3>韦德布什对微软的看法</h3>分析师Daniel Ives预计微软周二的盈利和指引将“超越并加薪”。</blockquote></p><p> Azure deal sizes are “increasing markedly,” driven by an acceleration in enterprise-wide digital transformations to cloud architecture, said the analyst.</p><p><blockquote>这位分析师表示，在企业范围内向云架构数字化转型加速的推动下，Azure交易规模正在“显着增加”。</blockquote></p><p> Azure is in its early stages of the roll-out, penetrating only 35% of Microsoft’s installed base, he said. Microsoft’s Office 365 transition should continue to provide tailwinds in enterprise Azure adoption, said Ives.</p><p><blockquote>他表示，Azure正处于推出的早期阶段，仅渗透到微软35%的安装基础。Ives表示，微软的Office 365过渡应该会继续推动企业Azure的采用。</blockquote></p><p> Digital transformation has an estimated $1 trillion total addressable market, and Microsoft is incredibly well-positioned to deploy Azure and Office 365 as the backbone of cloud enterprise solutions, said the Wedbush analyst.</p><p><blockquote>Wedbush分析师表示，数字化转型的潜在市场总额估计为1万亿美元，微软在部署Azure和Office 365作为云企业解决方案的支柱方面处于非常有利的地位。</blockquote></p><p> Looking ahead, Wedbush maintains its Outperform rating on Microsoft with a $325 price target, mainly due to a growing cloud transformation story fueled by a currently large Microsoft software installed base.</p><p><blockquote>展望未来，Wedbush维持对微软跑赢大盘的评级，目标价为325美元，这主要是由于目前庞大的微软软件安装基础推动了云转型故事的不断增长。</blockquote></p><p> <b>MSFT Price Action: </b>Microsoft was trading down 0.43% to $288.43 at last check Monday.</p><p><blockquote><b>MSFT价格走势：</b>周一最后一次检查时，微软股价下跌0.43%，至288.43美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why These 3 Microsoft Analysts Are Bullish Ahead Of Q4 Results<blockquote>为什么这三位微软分析师在第四季度业绩公布前看好</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy These 3 Microsoft Analysts Are Bullish Ahead Of Q4 Results<blockquote>为什么这三位微软分析师在第四季度业绩公布前看好</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-07-27 11:03</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Microsoft Corp. </b>(NASDAQ:MSFT) is set to report&nbsp;fourth-quarter earnings following the market close on Tuesday, July 27. In anticipation of this earnings call, analysts at Citi, KeyBanc&nbsp;and Wedbush Securities have provided insight into the company’s market positioning.</p><p><blockquote><b>微软公司。</b>（纳斯达克股票代码：MSFT）将于7月27日星期二收盘后公布第四季度收益。为了应对这一盈利看涨期权，花旗、KeyBanc和Wedbush Securities的分析师提供了对该公司市场定位的见解。</blockquote></p><p> The consensus estimates project fourth-quarter EPS of&nbsp;$1.90 and revenue of&nbsp;$44.1&nbsp;billion.</p><p><blockquote>市场普遍预计第四季度每股收益为1.90美元，营收为441亿美元。</blockquote></p><p> <h3>Citi's Take On Microsoft</h3> “Recovering IT budgets, an uptick in expected reseller growth, signs of reacceleration in consumption models and slightly higher PC numbers vs. 3 months ago” have helped analyst Tyler Radke maintain a positive outlook for Microsoft’s fourth-quarter earnings. The analyst did not provide an exact EPS estimate.</p><p><blockquote><h3>花旗对微软的看法</h3>“IT预算的恢复、经销商预期增长的上升、消费模式重新加速的迹象以及PC数量较3个月前略有增加”帮助分析师泰勒·拉德克(Tyler Radke)维持了对微软第四季度盈利的积极展望。该分析师没有提供确切的每股收益估计。</blockquote></p><p> Longer-term, Microsoft remains Citi’s top large-cap play among North American application software, systems software, and interactive home entertainment stocks, the analyst said in a note.</p><p><blockquote>该分析师在一份报告中表示，从长远来看，微软仍然是花旗在北美应用软件、系统软件和互动家庭娱乐股票中排名第一的大盘股。</blockquote></p><p> The analyst maintained a Buy rating and raised the&nbsp;price target from $310 to $378.</p><p><blockquote>该分析师维持买入评级，并将目标价从310美元上调至378美元。</blockquote></p><p> <h3>KeyBanc's Take On Microsoft</h3> Microsoft is becoming increasingly strategically important in the realm of security, cloud migration&nbsp;and digital transformation, said KeyBanc's managing director and senior analyst of enterprise software Michael Turits.</p><p><blockquote><h3>KeyBanc对微软的看法</h3>KeyBanc董事总经理兼企业软件高级分析师Michael Turits表示，微软在安全、云迁移和数字化转型领域变得越来越重要。</blockquote></p><p> According to a survey of IT value-added resellers (VAR), security, Office 365&nbsp;and Azure are the top areas of spending as the world ushers in an enterprise shift to greater adoption of digital technologies, said the analyst.</p><p><blockquote>这位分析师表示，根据对IT增值经销商（VAR）的一项调查，随着世界迎来企业向更多采用数字技术的转变，安全、Office 365和Azure是最大的支出领域。</blockquote></p><p> The VAR survey additionally highlighted that Microsoft’s products rank highly against competitors, from dev-ops solutions such as GitHub to cloud solutions with Azure to security offerings,&nbsp;which surpassed Okta/Auth0, he said.</p><p><blockquote>他说，VAR调查还强调，微软的产品在竞争对手中排名很高，从GitHub等开发运营解决方案到Azure的云解决方案，再到安全产品，这些产品都超过了Okta/Auth0。</blockquote></p><p> The analyst reiterated an Overweight rating and increased the&nbsp;price target from $305 to $330.</p><p><blockquote>该分析师重申了跑赢大盘评级，并将目标价从305美元上调至330美元。</blockquote></p><p> <h3>Wedbush's Take On Microsoft</h3> Analyst Daniel Ives is expecting a “beat and raise” from Microsoft on&nbsp;earnings and guidance Tuesday.</p><p><blockquote><h3>韦德布什对微软的看法</h3>分析师Daniel Ives预计微软周二的盈利和指引将“超越并加薪”。</blockquote></p><p> Azure deal sizes are “increasing markedly,” driven by an acceleration in enterprise-wide digital transformations to cloud architecture, said the analyst.</p><p><blockquote>这位分析师表示，在企业范围内向云架构数字化转型加速的推动下，Azure交易规模正在“显着增加”。</blockquote></p><p> Azure is in its early stages of the roll-out, penetrating only 35% of Microsoft’s installed base, he said. Microsoft’s Office 365 transition should continue to provide tailwinds in enterprise Azure adoption, said Ives.</p><p><blockquote>他表示，Azure正处于推出的早期阶段，仅渗透到微软35%的安装基础。Ives表示，微软的Office 365过渡应该会继续推动企业Azure的采用。</blockquote></p><p> Digital transformation has an estimated $1 trillion total addressable market, and Microsoft is incredibly well-positioned to deploy Azure and Office 365 as the backbone of cloud enterprise solutions, said the Wedbush analyst.</p><p><blockquote>Wedbush分析师表示，数字化转型的潜在市场总额估计为1万亿美元，微软在部署Azure和Office 365作为云企业解决方案的支柱方面处于非常有利的地位。</blockquote></p><p> Looking ahead, Wedbush maintains its Outperform rating on Microsoft with a $325 price target, mainly due to a growing cloud transformation story fueled by a currently large Microsoft software installed base.</p><p><blockquote>展望未来，Wedbush维持对微软跑赢大盘的评级，目标价为325美元，这主要是由于目前庞大的微软软件安装基础推动了云转型故事的不断增长。</blockquote></p><p> <b>MSFT Price Action: </b>Microsoft was trading down 0.43% to $288.43 at last check Monday.</p><p><blockquote><b>MSFT价格走势：</b>周一最后一次检查时，微软股价下跌0.43%，至288.43美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","09086":"华夏纳指-U","MSFT":"微软"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154966721","content_text":"Microsoft Corp. (NASDAQ:MSFT) is set to report fourth-quarter earnings following the market close on Tuesday, July 27. In anticipation of this earnings call, analysts at Citi, KeyBanc and Wedbush Securities have provided insight into the company’s market positioning.\nThe consensus estimates project fourth-quarter EPS of $1.90 and revenue of $44.1 billion.\nCiti's Take On Microsoft\n“Recovering IT budgets, an uptick in expected reseller growth, signs of reacceleration in consumption models and slightly higher PC numbers vs. 3 months ago” have helped analyst Tyler Radke maintain a positive outlook for Microsoft’s fourth-quarter earnings. The analyst did not provide an exact EPS estimate.\nLonger-term, Microsoft remains Citi’s top large-cap play among North American application software, systems software, and interactive home entertainment stocks, the analyst said in a note.\nThe analyst maintained a Buy rating and raised the price target from $310 to $378.\nKeyBanc's Take On Microsoft\nMicrosoft is becoming increasingly strategically important in the realm of security, cloud migration and digital transformation, said KeyBanc's managing director and senior analyst of enterprise software Michael Turits.\nAccording to a survey of IT value-added resellers (VAR), security, Office 365 and Azure are the top areas of spending as the world ushers in an enterprise shift to greater adoption of digital technologies, said the analyst.\nThe VAR survey additionally highlighted that Microsoft’s products rank highly against competitors, from dev-ops solutions such as GitHub to cloud solutions with Azure to security offerings, which surpassed Okta/Auth0, he said.\nThe analyst reiterated an Overweight rating and increased the price target from $305 to $330.\nWedbush's Take On Microsoft\nAnalyst Daniel Ives is expecting a “beat and raise” from Microsoft on earnings and guidance Tuesday.\nAzure deal sizes are “increasing markedly,” driven by an acceleration in enterprise-wide digital transformations to cloud architecture, said the analyst.\nAzure is in its early stages of the roll-out, penetrating only 35% of Microsoft’s installed base, he said. Microsoft’s Office 365 transition should continue to provide tailwinds in enterprise Azure adoption, said Ives.\nDigital transformation has an estimated $1 trillion total addressable market, and Microsoft is incredibly well-positioned to deploy Azure and Office 365 as the backbone of cloud enterprise solutions, said the Wedbush analyst.\nLooking ahead, Wedbush maintains its Outperform rating on Microsoft with a $325 price target, mainly due to a growing cloud transformation story fueled by a currently large Microsoft software installed base.\nMSFT Price Action: Microsoft was trading down 0.43% to $288.43 at last check Monday.","news_type":1,"symbols_score_info":{"09086":0.9,"03086":0.9,"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":829748320,"gmtCreate":1633561954911,"gmtModify":1633561955107,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829748320","repostId":"2173948202","repostType":4,"isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":802373672,"gmtCreate":1627725469496,"gmtModify":1631889015157,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Like me pls","listText":"Like me pls","text":"Like me pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/802373672","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":879786919,"gmtCreate":1636773124448,"gmtModify":1636773124448,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Vaccine","listText":"Vaccine","text":"Vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879786919","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":4307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":802503651,"gmtCreate":1627785572073,"gmtModify":1631889015157,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"I like Tsla. Like my comment pls","listText":"I like Tsla. Like my comment pls","text":"I like Tsla. Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/802503651","repostId":"1169518272","repostType":4,"isVote":1,"tweetType":1,"viewCount":218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":877689986,"gmtCreate":1637924331182,"gmtModify":1637924331182,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Hooray","listText":"Hooray","text":"Hooray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877689986","repostId":"1190474385","repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=zh_CN&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-26 18:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华","RHHBY":"罗氏控股"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1,"symbols_score_info":{"NVS":0.9,"RHHBY":0.9}},"isVote":1,"tweetType":1,"viewCount":3473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":837933922,"gmtCreate":1629851686666,"gmtModify":1631889015126,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/837933922","repostId":"2162087564","repostType":4,"isVote":1,"tweetType":1,"viewCount":191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":845842779,"gmtCreate":1636331128796,"gmtModify":1636331128935,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845842779","repostId":"1125924899","repostType":4,"repost":{"id":"1125924899","kind":"news","pubTimestamp":1636330179,"share":"https://www.laohu8.com/m/news/1125924899?lang=zh_CN&edition=full","pubTime":"2021-11-08 08:09","market":"sh","language":"en","title":"Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record<blockquote>供应链问题抑制了巴菲特旗下伯克希尔哈撒韦公司的利润；现金创下纪录</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125924899","media":"Reuters","summary":"Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply","content":"<p>Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.</p><p><blockquote>路透11月6日-沃伦·巴菲特的伯克希尔·哈撒韦公司(BRKa.N)周六表示，全球供应链中断限制了其盈利能力，而股价上涨导致其出售部分股票并将现金储备增加至创纪录水平。</blockquote></p><p> Operating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.</p><p><blockquote>营业利润增长18%，但未达到分析师预期，因为冠状病毒德尔塔变异毒株引发的COVID-19病例死灰复燃导致商品短缺并抑制了消费者支出，而飓风艾达和欧洲洪水造成的损失增加了Geico汽车保险公司和其他保险单位的承保损失。</blockquote></p><p> Net income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).</p><p><blockquote>与此同时，净利润下降了66%，反映出苹果(AAPL.O)和$Bank of America Corp(BAC-N)$(BAC.N)等股票的收益下降。</blockquote></p><p> Berkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.</p><p><blockquote>伯克希尔在第三季度回购了76亿美元的自有股票，今年回购了202亿美元，因为股市上涨使得收购整个公司的成本越来越高。</blockquote></p><p> The buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.</p><p><blockquote>此次回购似乎在10月份仍在继续，这表明91岁的亿万富翁巴菲特认为自己位于内布拉斯加州奥马哈的企业集团具有更大的价值，该集团的业务包括BNSF铁路和同名能源部门。</blockquote></p><p> \"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"</p><p><blockquote>CFRA Research分析师凯茜·塞弗特(Cathy Seifert)表示：“最大的室内游戏之一是，伯克希尔哈撒韦的下一项重大收购是什么。”对伯克希尔哈撒韦给予“持有”评级。“我想我们刚刚看到了：它回购了200亿美元的自己的股票。”</blockquote></p><p> Berkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.</p><p><blockquote>伯克希尔也是股票的净卖家，本季度卖出的股票比买入的多了约20亿美元。截至9月底，该公司拥有1,492亿美元现金及等价物。</blockquote></p><p> \"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones &amp; Co analyst who rates Berkshire a \"buy.\"</p><p><blockquote>爱德华·琼斯公司(Edward Jones&amp;Co)分析师吉姆·沙纳汉(Jim Shanahan)表示：“我确实希望会有更多回购，因为没有太多证据表明资本正在发挥作用。”他将伯克希尔评级为“买入”。</blockquote></p><p> DISRUPTIONS</p><p><blockquote>中断</blockquote></p><p> Third-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.</p><p><blockquote>第三季度营业利润从去年同期的54.8亿美元（约合每股3488美元）升至64.7亿美元（约合每股4331美元）。</blockquote></p><p> Analysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.</p><p><blockquote>根据Refinitiv I/B/E/S的数据，分析师平均预测为每股4,493美元。</blockquote></p><p> Net income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.</p><p><blockquote>净利润从301亿美元降至103亿美元，即每股A股6882美元。巴菲特认为，净利润的巨大季度波动通常毫无意义，是他无法控制的会计规则造成的。</blockquote></p><p> Berkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.</p><p><blockquote>伯克希尔表示，供应链中断推高了材料和运费的价格，迫使Clayton Homes mobile homes和Acme bricks等企业提高价格，并导致McLane grocery distribution卡车司机短缺。</blockquote></p><p> It said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.</p><p><blockquote>该公司表示，这些中断还大幅减少了其汽车经销商部门的新车销量，并增加了其消费品业务的成本，尽管Forest River房车、Brooks跑鞋和金霸王电池的利润正在上升。</blockquote></p><p> In part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.</p><p><blockquote>部分由于达美航空和劳动力短缺造成的干扰，根据政府的预先估计，美国第三季度国内生产总值年化增长率为2%，低于第二季度的6.7%。</blockquote></p><p> \"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo &amp; Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.</p><p><blockquote>宾夕法尼亚州兰开斯特Gardner Russo&amp;Quinn合伙人汤姆·鲁索(Tom Russo)表示：“供应链造成了瓶颈，不可避免地会影响伯克希尔铁路的负载，并导致其住房业务出现短缺。”该公司自1982年以来一直持有伯克希尔股票。</blockquote></p><p> CATASTROPHE LOSSES</p><p><blockquote>灾害损失</blockquote></p><p> Results reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.</p><p><blockquote>结果反映了分析师沙纳汉所说的“极高”的22亿美元巨灾损失，主要来自Ida和洪水，尽管其他保险公司也遭受了巨额损失。</blockquote></p><p> Geico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.</p><p><blockquote>仅Geico就因承保损失2.89亿美元，受到Ida和车祸增加的影响。</blockquote></p><p> In contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.</p><p><blockquote>相比之下，BNSF的利润增长了14%，达到15.4亿美元，因为工业品和煤炭产量的增加抵消了谷物出口的下降。</blockquote></p><p> Buffett's failure to buy more stocks and companies has disappointed some investors and analysts.</p><p><blockquote>巴菲特未能买入更多股票和公司，令一些投资者和分析师感到失望。</blockquote></p><p> It stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.</p><p><blockquote>这部分源于让私营公司上市的特殊目的收购公司（SPAC）如何推高收购目标的价格。</blockquote></p><p> \"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.</p><p><blockquote>“这是一个杀手，”巴菲特在5月1日的伯克希尔年会上说道。</blockquote></p><p> CFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.</p><p><blockquote>CFRA Research分析师塞弗特表示，伯克希尔不会永远袖手旁观，可能会在2022年着眼于收购其长期青睐的行业，包括工业和消费必需品。</blockquote></p><p> \"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, <a href=\"https://laohu8.com/S/AONE.U\">one</a> can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.</p><p><blockquote>“鉴于精密铸件和卡夫亨氏等备受瞩目的失误数量，<a href=\"https://laohu8.com/S/AONE.U\">一</a>我可以理解伯克希尔的一些沉默，”她说，指的是这家飞机零部件制造商和食品公司。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record<blockquote>供应链问题抑制了巴菲特旗下伯克希尔哈撒韦公司的利润；现金创下纪录</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record<blockquote>供应链问题抑制了巴菲特旗下伯克希尔哈撒韦公司的利润；现金创下纪录</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-08 08:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.</p><p><blockquote>路透11月6日-沃伦·巴菲特的伯克希尔·哈撒韦公司(BRKa.N)周六表示，全球供应链中断限制了其盈利能力，而股价上涨导致其出售部分股票并将现金储备增加至创纪录水平。</blockquote></p><p> Operating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.</p><p><blockquote>营业利润增长18%，但未达到分析师预期，因为冠状病毒德尔塔变异毒株引发的COVID-19病例死灰复燃导致商品短缺并抑制了消费者支出，而飓风艾达和欧洲洪水造成的损失增加了Geico汽车保险公司和其他保险单位的承保损失。</blockquote></p><p> Net income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).</p><p><blockquote>与此同时，净利润下降了66%，反映出苹果(AAPL.O)和$Bank of America Corp(BAC-N)$(BAC.N)等股票的收益下降。</blockquote></p><p> Berkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.</p><p><blockquote>伯克希尔在第三季度回购了76亿美元的自有股票，今年回购了202亿美元，因为股市上涨使得收购整个公司的成本越来越高。</blockquote></p><p> The buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.</p><p><blockquote>此次回购似乎在10月份仍在继续，这表明91岁的亿万富翁巴菲特认为自己位于内布拉斯加州奥马哈的企业集团具有更大的价值，该集团的业务包括BNSF铁路和同名能源部门。</blockquote></p><p> \"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"</p><p><blockquote>CFRA Research分析师凯茜·塞弗特(Cathy Seifert)表示：“最大的室内游戏之一是，伯克希尔哈撒韦的下一项重大收购是什么。”对伯克希尔哈撒韦给予“持有”评级。“我想我们刚刚看到了：它回购了200亿美元的自己的股票。”</blockquote></p><p> Berkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.</p><p><blockquote>伯克希尔也是股票的净卖家，本季度卖出的股票比买入的多了约20亿美元。截至9月底，该公司拥有1,492亿美元现金及等价物。</blockquote></p><p> \"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones &amp; Co analyst who rates Berkshire a \"buy.\"</p><p><blockquote>爱德华·琼斯公司(Edward Jones&amp;Co)分析师吉姆·沙纳汉(Jim Shanahan)表示：“我确实希望会有更多回购，因为没有太多证据表明资本正在发挥作用。”他将伯克希尔评级为“买入”。</blockquote></p><p> DISRUPTIONS</p><p><blockquote>中断</blockquote></p><p> Third-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.</p><p><blockquote>第三季度营业利润从去年同期的54.8亿美元（约合每股3488美元）升至64.7亿美元（约合每股4331美元）。</blockquote></p><p> Analysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.</p><p><blockquote>根据Refinitiv I/B/E/S的数据，分析师平均预测为每股4,493美元。</blockquote></p><p> Net income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.</p><p><blockquote>净利润从301亿美元降至103亿美元，即每股A股6882美元。巴菲特认为，净利润的巨大季度波动通常毫无意义，是他无法控制的会计规则造成的。</blockquote></p><p> Berkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.</p><p><blockquote>伯克希尔表示，供应链中断推高了材料和运费的价格，迫使Clayton Homes mobile homes和Acme bricks等企业提高价格，并导致McLane grocery distribution卡车司机短缺。</blockquote></p><p> It said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.</p><p><blockquote>该公司表示，这些中断还大幅减少了其汽车经销商部门的新车销量，并增加了其消费品业务的成本，尽管Forest River房车、Brooks跑鞋和金霸王电池的利润正在上升。</blockquote></p><p> In part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.</p><p><blockquote>部分由于达美航空和劳动力短缺造成的干扰，根据政府的预先估计，美国第三季度国内生产总值年化增长率为2%，低于第二季度的6.7%。</blockquote></p><p> \"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo &amp; Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.</p><p><blockquote>宾夕法尼亚州兰开斯特Gardner Russo&amp;Quinn合伙人汤姆·鲁索(Tom Russo)表示：“供应链造成了瓶颈，不可避免地会影响伯克希尔铁路的负载，并导致其住房业务出现短缺。”该公司自1982年以来一直持有伯克希尔股票。</blockquote></p><p> CATASTROPHE LOSSES</p><p><blockquote>灾害损失</blockquote></p><p> Results reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.</p><p><blockquote>结果反映了分析师沙纳汉所说的“极高”的22亿美元巨灾损失，主要来自Ida和洪水，尽管其他保险公司也遭受了巨额损失。</blockquote></p><p> Geico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.</p><p><blockquote>仅Geico就因承保损失2.89亿美元，受到Ida和车祸增加的影响。</blockquote></p><p> In contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.</p><p><blockquote>相比之下，BNSF的利润增长了14%，达到15.4亿美元，因为工业品和煤炭产量的增加抵消了谷物出口的下降。</blockquote></p><p> Buffett's failure to buy more stocks and companies has disappointed some investors and analysts.</p><p><blockquote>巴菲特未能买入更多股票和公司，令一些投资者和分析师感到失望。</blockquote></p><p> It stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.</p><p><blockquote>这部分源于让私营公司上市的特殊目的收购公司（SPAC）如何推高收购目标的价格。</blockquote></p><p> \"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.</p><p><blockquote>“这是一个杀手，”巴菲特在5月1日的伯克希尔年会上说道。</blockquote></p><p> CFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.</p><p><blockquote>CFRA Research分析师塞弗特表示，伯克希尔不会永远袖手旁观，可能会在2022年着眼于收购其长期青睐的行业，包括工业和消费必需品。</blockquote></p><p> \"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, <a href=\"https://laohu8.com/S/AONE.U\">one</a> can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.</p><p><blockquote>“鉴于精密铸件和卡夫亨氏等备受瞩目的失误数量，<a href=\"https://laohu8.com/S/AONE.U\">一</a>我可以理解伯克希尔的一些沉默，”她说，指的是这家飞机零部件制造商和食品公司。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125924899","content_text":"Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.\nOperating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.\nNet income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).\nBerkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.\nThe buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.\n\"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"\nBerkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.\n\"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones & Co analyst who rates Berkshire a \"buy.\"\nDISRUPTIONS\nThird-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.\nAnalysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.\nNet income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.\nBerkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.\nIt said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.\nIn part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.\n\"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo & Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.\nCATASTROPHE LOSSES\nResults reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.\nGeico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.\nIn contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.\nBuffett's failure to buy more stocks and companies has disappointed some investors and analysts.\nIt stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.\n\"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.\nCFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.\n\"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, one can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.","news_type":1,"symbols_score_info":{"BRK.B":0.9,"BRK.A":0.9}},"isVote":1,"tweetType":1,"viewCount":2631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854245705,"gmtCreate":1635465395781,"gmtModify":1635465395921,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854245705","repostId":"1147570640","repostType":4,"isVote":1,"tweetType":1,"viewCount":746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}